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Summary 
It is estimated that the prevalence of persons with rare diseases in Norway is 
approximately 30 000, a number that has increased due to new technology that 
makes it possible to describe new diseases. In Norway, a disease is termed rare if 
the prevalence is less than 1 case in 10 000 people. Overall, more than 80% of rare 
diseases are caused by genetic defects.  
Lymphoedema cholestasis syndrome 1 (LCS1), or Aagenaes syndrome, is one such 
rare disease, with nearly 100 diagnosed cases worldwide. Oystein Aagenaes, for 
whom the disease is named, was one of the first to describe this disease in 1968. 
Most patients originate from south-western Norway. Presently a total of 48 persons in 
Norway have been diagnosed with LCS1. The large number of cases recorded within 
our country is believed to be due to a founder effect.  
The main challenge in these patients is neonatal cholestasis which causes 
malabsorption of fat and fat-soluble vitamins. If untreated, the condition leads to 
rickets, neuropathy and serious growth retardation or death due to haemorrhage. In 
some patients, cholestasis leads to end-stage liver disease. In adult patients, 
although periods of recurrent cholestasis might be distressing, primary lymphoedema 
is typically a greater concern.  
The overall aim of this work has been to obtain new evidence-based knowledge 
about the progression of liver disease in a group of adolescent and adult patients 
with LCS1, to evaluate the need for the treatment of liver disease outside cholestatic 
periods or the treatment of lymphoedema. These aims have been supported by the 
Centre for Rare Disorders (SSD), one of ten nationwide interdisciplinary competence 
centres working with rare diseases on the behalf of the Norwegian Ministry of Health 
and Care Services.  
In conclusion, although the overall prognosis in LCS1 is highly variable, and is largely 
dependent on the progression of cholestasis, patients with LCS1 exhibit a relatively 
good prognosis compared with other types of hereditary neonatal cholestasis. More 
than 50% of patients can probably expect a normal life span. Data presented in this 
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thesis show that adults who have survived the initial prolonged period of cholestasis 
and exhibit stable liver disease may have an even better prognosis. Approximately 
one-third of patients with LCS1 exhibit severe extremity lymphoedema and require 
close follow-up; however, lymphoedema is generally well managed with compression 
of lower limbs and CDT treatment. The diet of the LCS1 patient group is similar to 
that of healthy controls, with only few deviations from the Norwegian dietary 
recommendations.  
Overall, the care and follow-up of LCS1 patients in this group seems satisfactory, but 
patients could benefit from following Norwegian dietary guidelines, with specific 
emphasis on carbohydrate and fat quality, in addition to regular monitoring of the 
blood levels of vitamins D and E.  
The findings presented in this paper may provide potentially valuable information for 
adult LCS1 patients worldwide.  
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1 Introduction 
1.1 Rare diseases 
Rare diseases are defined differently throughout the world. In Norway, a congenital 
disease with a prevalence of less than 1 known case in 10 000 inhabitants is termed 
rare [1, 2] and corresponds to a total less than 500 cases among the Norwegian 
population. For most rare diseases, far fewer than 500 individuals have been 
diagnosed with the same condition [3]; in Norway, approximately 30 000 persons are 
estimated to have been diagnosed with a rare disease [3].  
In the European Union (EU) countries, any disease affecting fewer than 5 people in 
10 000 is considered rare. In the EU, it is estimated that 6 000 - 8 000 distinct rare 
diseases affect 6 - 8% of the population, representing between 27 - 36 million 
affected individuals [4]. This wide range is attributed to variations in how rare 
diseases are diagnosed within EU countries and the increasing emergence of new 
technologies to identify new diseases. In the United States (US), a disease is 
considered rare if it affects less than 200 000 Americans [5]. More than 80% of rare 
diseases are caused by genetic defects [6]. 
In Norway, there are ten interdisciplinary nationwide competence centres working 
with rare diseases on behalf of the Norwegian Ministry of Health and Care Services 
[1]. These national competence centres are part of the specialist health care services 
in Norway and currently provide support for more than 300 rare diseases. The 
centres concentrate on knowledge development, including scientific studies, and 
spreading competence in cooperation with the specialist health care system and 
community-based health care services. In addition, the centres provide information 
and counselling aimed directly at persons with a rare disease and their close 
relations [1]. Only individuals with rare diseases that are known to require extensive 
support and services in addition to the medical treatments provided by other parts of 
the health care system receive services from these centres.  
The Centre for Rare Disorders (Senter for sjeldne diagnoser (SSD)) at Oslo 
University Hospital (OUS) HF is one such centre with a mandate to acquire 
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specialists with knowledge and experience with more than 70 different rare diseases 
[7, 8]. One of these diseases is Aagenaes syndrome/Lymphoedema cholestasis 
syndrome 1 (LCS1).  
1.2  A brief overview of LCS1 
Aagenaes syndrome was named after the Norwegian professor Dr Oystein 
Aagenaes, who was one of the first individuals to describe the condition in the 1960s 
[9]. The syndrome includes liver disease that manifests as idiopathic intrahepatic 
cholestasis and lymphoedema caused by lymph vessel hypoplasia [10]. Aagenaes 
syndrome has officially been named lymphoedema cholestasis syndrome 1 (LCS1) 
by the Human Genome Organisation’s (HUGO) Gene Nomenclature Committee 
(HGNC) [11] and has the Online Mendelian Inheritance in Man (OMIM) number 
214900 [12]. In this thesis, the abbreviation LCS1 will be used to refer to this disease. 
In LCS1, a strong emphasis on dietary and medical follow-up is needed during 
infancy and childhood because of cholestasis. Adolescent and adult patients have 
few cholestatic periods. It is unknown whether the liver disease affects individual 
patients in the absence of cholestasis or whether affected patients require dietary 
advice outside such periods. The lymphoedema is a daily concern for the patients 
and an evaluation of the lymphoedema variations within the group of LCS1 has been 
conducted.  
In the following sections, an introduction to both cholestatic liver disease and 
lymphoedema is presented.  
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2 Liver disease 
Liver disease includes a wide range of conditions (more than 100) that can be 
inherited or occur in response to viruses or chemicals. Liver diseases can either be 
acute or chronic and may lead to cirrhosis. Cirrhosis is the ultimate pathological 
feature of all forms of chronic hepatic injury. Irrespective of the cause of liver disease, 
destruction of the hepatic architecture and vascular structures, (Figure 1), in 
conjunction with the deposition of fibrotic tissue leads to the functional 
decompensation of the liver [13].  
Difficulties in accessing data from individual countries hinder the global evaluation of 
liver disease, but approximately 29 million people in the EU suffer from a chronic liver 
condition [14]. The four leading causes of cirrhosis and primary liver cancer in 
Europe include harmful alcohol consumption, viral hepatitis B and C, and metabolic 
syndromes (non-alcoholic fatty liver disease (NAFLD)) that are related to overweight 
and obesity [14]Ǥ
According to the World Health Organization (WHO), available data suggest that 
approximately 0.1% of the European population is affected by cirrhosis; this 
estimation corresponds to 1.4 - 2.6 new cases per 10 000 inhabitants per year and 
an estimated 170 000 deaths annually [15]. An estimated 400 new cases of acute 
liver failure are diagnosed annually (corresponding to 0.06 per 10 000) in the United 
Kingdom (UK) [16], and the estimated prevalence rate is 0.05 per 10 000 in Germany 
[17]. In the US, chronic liver disease has an estimated prevalence of approximately 
6.4 cases per 10 000 individuals [18], whereas acute liver failure is estimated to have 
an annual incidence of 2 300-2 800, corresponding to 0.07 - 0.09 cases per 10 000 
individuals [16].  
 
2.1 Cholestatic liver disease 
Cholestasis is one of the most common and devastating manifestations of liver 
disease [19]. Cholestasis is a condition that results from impaired bile acid synthesis 
or bile flow to the gallbladder and duodenum and clinically presents with fatigue, 
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pruritus (itching), and jaundice [20]. Cholestasis may be classified as intrahepatic or 
extrahepatic, and may be of acute or chronic origin. The chronic cholestatic diseases 
are most often of intrahepatic origin. Cholestasis is considered chronic if it persists 
more than 6 months [21]. 
A variety of conditions cause cholestasis both in infancy and adulthood [22]. The most 
common causes of chronic liver disease in children are inherited syndromes of 
intrahepatic cholestasis, e.g., Alagille syndrome, progressive familial intrahepatic 
cholestasis (PFIC) [23], and biliary atresia [24]. Even the most common of these 
conditions is rare. The most accurate figures estimate the rate of biliary atresia to 
range from 1 in 17 000 to 19 000 live births [25]. Estimates of the incidence of 
Alagille syndrome range from 1 in 30 000 to 50 000 live births [26]. The true 
incidence of PFIC is not precisely known, but it is considered a rare disease with an 
estimated incidence ranging from 1 in 50 000 to 100 000 births [27].  
 
Figure 1. Three-dimensional histological structure of human liver. Reprinted with 
permission from Encyclopædia Britannica Online. Web. 21 Jun. 2014. 
 
The most common cause of chronic intrahepatic cholestatic liver disease in adults is 
primary biliary cirrhosis (PBC). The second most common cause is primary 
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sclerosing cholangitis (PSC), which also damages the extrahepatic bile ducts. 
Throughout the world, the incidence and prevalence rates of PBC and PSC vary 
widely [21, 28, 29]. The mean annual incidence rates for PBC and PSC per 100 000 
in Norway have been estimated at 1.6 and 1.3, respectively (with a point prevalence 
per 100 000 of 14.6 and 8.5, respectively) [30]. In PBC, the incidence and prevalence 
rate in different countries, range from 0.33 - 5.8 and 1.9 - 40.2 per 100 000 
inhabitants, respectively [28]. The estimated combined incidence rate of PSC in 
North America and Europe is 1 per 100 000 inhabitants, and the prevalence rate is 0 
- 16.2 per 100 000 inhabitants [28]. 
 
2.2 Genetics in cholestatic disease 
The dominant pathway for cholesterol elimination from the body is bile acid formation 
and involves more than 15 enzymes in the hepatocytes. The individual steps are 
important, and any defects in these enzymes can lead to clinical manifestations of 
cholestatic liver disease. In the small intestine, bile acids solubilise dietary lipids and 
fat-soluble vitamins, promoting their absorption. Bile acids are cytotoxic when present 
in high concentrations [31], and both the synthesis and transport of bile acids are 
highly regulated processes that occur principally in the liver [19, 32].  
Four key nuclear hormone receptors regulate bile acid homeostasis (Figure 2); the 
farnesoid X receptor (FXR), the vitamin D receptor (VDR), the pregnane X receptor 
(PXR) also known as the steroid and xenobiotic sensing nuclear receptor (SXR), and 
the liver X receptor (LXR) [19]. FXR, PXR/SXR and VDR bind bile acids and are 
therefore sensors of excessive amounts of bile acids [19]. During the last decade, 
many genetic loci associated with intrahepatic cholestasis have been mapped, and 
the corresponding genes have been identified; reported examples include mutations 
in cytochrome enzymes, such as cytochrome P450 7A1 (CYP7A1) or CYP7B1; ATP-
binding cassette transporter B11 (ABCB11); ATPase class I, type 8B, and member 1 
(ATP8B1) proteins; multi-drug-resistant protein 3 (MDR3); tight junction protein 2 
(TJP2); and vacuolar protein sorting 33 homolog B (VPS33B) [19, 33].  
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The major pathway for bile acid synthesis is the neutral pathway; its first step is the 
hydroxylation of the carbon atom at C-7 in the cholesterol molecule by CYP7A1. The 
second step is hydroxylation at C-12 which is mediated by CYP7B1. The CYP27A1 
initiates the alternative bile acid biosynthetic pathway. The CYP7A1 is a microsomal 
enzyme and is considered to be the rate-limiting step in bile acid synthesis [32, 34]. 
After bile acids have been formed from cholesterol, they undergo amide linkage to 
glycine and taurine between the carboxyl group of the bile acid and the amino group 
of glycine and taurine, a process known as conjugation. The conjugation of bile acids 
has a number of biological and physiochemical consequences, and makes them 
impermeable to the membranes of hepatocytes, cholangiocytes and enterocytes 
thereby permitting high bile acid concentrations to accumulate in these 
compartments. Bile acids are deconjugated when they are exposed to bacteria in the 
intestine. Deconjugation and dehydroxylation decrease the solubility of bile acids and 
increase their toxicity [34].  
In the enterohepatic circulation bile acids circulate between the liver and the small 
intestine. Most of the bile acids that return to the liver are in their conjugated form 
and only a minority are deconjugated. The uptake of bile acids in the enterohepatic 
circulation is 50-90% and is highly efficient. Bile acid circulation exhibits two modes 
of regulation. The first is negative feedback of bile acid synthesis from cholesterol in 
the hepatocytes. The second is negative feedback regulation of bile acid transport in 
the ileal enterocytes. Both of these regulatory mechanisms are driven by the 
intracellular concentration of bile acids acting on the nuclear receptor FXR. In the 
nucleus, bile acids bind to FXR. An FXR-RXR heterodimer acts to stimulate the 
synthesis of an inhibitory protein SHP, which in turn displaces a promoter factor 
(HNF4) from the promoter of the CYP7A1 gene. An additional essential negative 
regulatory factor is FGF15, a peptide secreted by the ileal enterocyte. This peptide 
acts on a basolateral receptor FGF4 which ultimately suppresses CYP7A1 
transcription via a JNK-mediated pathway. The end result of these complex 
regulatory circuits is the down-regulation of bile acid synthesis through elevated bile 
acid levels using negative feedback modulated by FXR [32].  
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Role of nuclear hormone receptors in transcriptional regulation of bile acid synthesis and 
transport. 
van Mil S W C et al. J Med Genet 2005;42:449-463
©2005 by BMJ Publishing Group Ltd
 
Figure 2. The role of nuclear hormone receptors in the transcriptional regulation of bile acid synthesis 
and transport. In response to high concentrations of bile acids, bile acid synthesis and absorption in 
the hepatocytes decrease, whereas bile salt secretion and detoxification increase due to the action of 
nuclear hormone receptors. In the enterocyte, detoxification of secondary bile acids is increased and 
the secretion of bile acids into the portal venous system is eventually enhanced by transcriptional 
activation of Intestinal Bile Acid Binding Protein (IBABP). (Reprinted with permission from BMJ 
Publishing Group Ltd. and Journal of Medical Genetics, License Number 3405800367987, license 
date Jun 11, 2014). 
 
In addition to CYP7A1, other genes regulated by FXR include SLC10A1 and the 
gene encoding NTCP1, a sodium-dependent co-transporter that is involved in 
conjugated bile acid uptake. SLC10A1 is down regulated by FXR activation. ABCB11 
the gene encoding the bile salt export pump (BSEP), is up-regulated. Therefore, the 
end result of FXR activation is to decrease the concentration of bile acids in all 
hepatocytes [32].  
Numerous familial and congenital cholestatic disorders are caused by genetic 
mutations [19, 35-38]. The pathogenesis of biliary atresia is unknown [39]. Alagille 
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syndrome is an autosomal dominant disorder caused by mutations in the Jagged 1 
(JAG1) gene and the NOTCH receptor (a single transmembrane protein that is 
partially present at the cell surface) [40, 41]. The JAG1 gene encodes a ligand for the 
NOTCH receptor and thus is part of a signalling pathway that is critical during 
development [40, 41]. 
Other common inherited cholestatic diseases caused by mutations in the 
hepatocellular transport system genes involved in bile synthesis have been described 
by Hartley at al [38]. Both PFIC1 and benign recurrent intrahepatic cholestasis 
(BRIC1) are caused by mutations in ATP8B1. PFIC2 and BRIC2 are caused by 
mutations in ABCB11, also known as BSEP deficiency. PFIC3 known as MDR3 
deficiency is caused by mutations in ABCB4 
Other familial intrahepatic cholestasis syndromes, such as arthrogryposis, renal 
dysfunction and cholestasis syndrome (ARC-syndrome) are caused by recessive 
mutations in VPS33B at chromosome 15q26.1 [42]. North American Indian childhood 
cirrhosis (NAICC) is caused by mutations in CIRHA1A, which encodes a protein of 
unknown function [43]. Advances in the understanding of gene defects underlying 
familial cholestasis syndromes have greatly increased our knowledge regarding the 
processes of bile flow and regulation [19].  
2.3 Diagnosing the cause of cholestasis 
There is a broad range of differential diagnosis for cholestasis, especially in infancy 
and childhood, but also in adults [22, 37].  
Early biochemical markers in patients (who are often otherwise asymptomatic) 
include increases in serum alkaline phosphatase (ALP) and Ȗ-glutamyltranspeptidase 
(Ȗ-GT), followed by conjugated hyperbilirubinaemia at more advanced stages [22]. 
Isolated serum ALP elevation is observed in cholestatic liver diseases, including 
certain rare diseases (e.g., bile acid synthesis defects in PFIC 1 and 2), but may also 
result from rapid bone growth (e.g., in infants and children), bone disease (e.g., 
Paget’s disease), or pregnancy [22, 44].  
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In patients who present with cholestatic symptoms such as jaundice, fatigue, pruritus, 
dark colored urine, and/ or light colored stools, the first critical step is to differentiate 
intra- from extra hepatic cholestasis. The presence of extra hepatic pathologies such 
as biliary atresia should be ruled out early in the course of the evaluation as such 
conditions may be reversible [21, 45]. A careful patient history and physical 
examination are essential in the diagnostic process [22]. A family history of 
cholestatic liver disease suggests the possibility of a hereditary disorder.  
Instruments and methods used to diagnose cholestasis include abdominal 
ultrasonography, magnetic resonance cholangiopancreatography (MRCP), testing for 
serum antimitochondrial antibodies (AMA) in adults and liver biopsy in cases where 
the diagnosis is still unclear [22].  
Rates of dyslipidemia, portal hypertension and malignancies such as hepatocellular 
carcinoma and cholangiocarcinoma are increased in the setting of cholestatic 
disease [21]. 
 
2.4 Treatment of cholestasis 
Medical treatment 
The major aim of the treatment for all forms of cholestasis is to reduce the retention 
of bile acids and other bile constituents in the hepatocytes and improve liver function 
[46]. In most cholestatic diseases, the cause is unknown, and therapy can only be 
directed toward the suppression of the pathogenetic process [46]. Nuclear receptors 
have been recognised as potential targets for the pharmacologic treatment of 
cholestasis [46].  
Cholestyramine, colestipol, and colesevelam bind bile acids and remove them from 
the circulation. With steady-state administration of such medicines bile acid synthesis 
(and loss) can increase by a factor of 4. All of these agents decrease pruritus in 
cholestatic liver disease, provided that bile acid secretion into the intestine is 
sufficient [32]. The most troublesome symptom of cholestasis is pruritus [21]. 
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Although clinical experience suggests that the degree of itching is closely related to 
the degree of increase in bile acids, the precise mechanism of cholestatic pruritus 
remains unclear [47]. Cholestyramine or colestipol can be used to alleviate pruritus; 
rifampicin, which is a strong agonist of PXR, can also be used as an alternative. 
Opioid antagonists, such as naltrexone or nalmefene, ameliorate the sensation of 
pruritus and can be used to treat itching [48]. Sertraline or ondansetron might also be 
beneficial [21]. Ursodeoxycholic acid (UDCA) has been demonstrated to exert 
anticholestatic effects in various cholestatic disorders [22]. UDCA acts as an FXR 
antagonist and increases bile acid secretion [49]. 
Surgical treatment 
At present, there are no definitive medical therapies that can provide curative options 
to affected patients. Liver transplantation is the only therapy for patients who have 
progressed to end-stage liver disease (ESLD) [50]. In children, biliary atresia and 
other cholestatic disorders are the most frequent cause of ESLD [51], but earlier 
surgical treatment of biliary atresia by the Kasai usually corresponds to later 
requirements of liver transplantation [45]. The Kasai procedure introduced in Japan in 
the 1960’s, was the first operation for biliary atresia and has saved the lives of many 
patients with biliary atresia [45]. ESLD manifests as depressed serum proteins, 
coagulopathy, cholestasis, malabsorption, malnutrition, portal hypertension, renal 
dysfunction, fluid and electrolyte imbalances, ascites, and encephalopathy from the 
accumulation of neurotoxins [51, 52]. Sixty percent to 80% of children with ESLD 
exhibit moderate to severe malnutrition prior to transplant [51]. 
Dietary treatment 
The prevalence of malnutrition in liver disease has been reported to be 65 - 90% [52], 
and cholestatic disorders are the most prevalent liver diseases associated with 
malnutrition [51]. A direct correlation exists between the progression of liver disease 
and the severity of malnutrition, and malnourished patients generally have a higher 
risk than well-nourished patients for adverse clinical outcomes and increased health-
care costs [52, 53]. Those at greatest risk of malnutrition from liver disease are 
children younger than 24 months, those with cholestasis, those awaiting liver 
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transplantation and patients with hepatic complications such as ascites and bleeding 
varices [51]. Ongoing individualised nutritional interventions are needed especially in 
infants and children [54].  
Major contributors to malnutrition include inadequate food intake, metabolic 
disturbances, malabsorption, and decreased capacity of the liver to store nutrients 
[53]. Decreased plasma concentrations of micronutrients in ESLD may occur 
secondary to impaired hepatic synthesis of the carrier proteins or from a down-
regulatory effect of systemic inflammation [51]. 
Nutrition screening and assessment are the first steps in nutrition care directed at 
improving the clinical outcomes of children and adults with chronic liver disease and 
ESLD [51-53]. The components of nutrition screening include anthropometry, 
physical assessment, dietary evaluation and biochemical tests [51, 53].  
When the flow of bile acids is restricted in patients with cholestasis, fat and fat-
soluble vitamins are poorly absorbed, and bile and bile acid components (e.g., 
bilirubin and cholesterol) accumulate [51-53]. Multiple fat-soluble vitamin deficiencies 
may be present in 20 - 35% of patients with cholestatic liver diseases [55]. Specific 
recommendations have been made for calcium, selenium, sodium, and vitamin A, D, 
E, and K supplementation (Table 1) [22]. Vitamin K deficiencies can cause life-
threatening internal bleeding. A lack of vitamin E can cause neurologic damage, and 
deficiencies of vitamin D can lead to rickets and dental problems [51, 53]. Water-
soluble vitamin deficiencies in patients with chronic liver disease can include 
pyridoxine, thiamine or vitamin B12 deficiency and may result in peripheral 
neuropathy and other neurological disturbances [53]. The zinc deficiency observed in 
liver disease may be due to diarrhoea, intestinal malabsorption, increased urinary 
losses or low protein intake [53].  
The nutritional goals in infants and children include the support of adequate growth 
and development; in adults the primary nutritional goal is to improve clinical 
outcomes. Stable patients exhibit near normal energy requirements, whereas more 
critically ill patients exhibit higher requirements. To account for higher metabolic rates 
increased calories must be provided. Infants and children are therefore particularly in 
need of a diet that is adapted according to individual growth, liver function and the 
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presence or absence of steatorrhoea. Breastfeeding accompanied by the fortification 
of the diet with infant formula that is high in medium chain triglycerides (MCT) to 
optimise fat absorption and to avoid essential fatty acid deficiencies is recommended 
in infants. Protein powders, glucose polymer powder and liquid fats can be added 
with vitamins and minerals to oral feeds, if needed [51]. Some patients may need 
additional enteral nutrition. An increase in sugar intake may result from a lower intake 
of energy from fat and may need to be addressed in conjunction with dental health 
care for older children and adults. Many patients with cirrhosis have glucose 
intolerance or diabetes. Infants and children are at increased risk of developing 
fasting hypoglycaemia due to reduced gluconeogenesis and a reduced capacity for 
glycogen storage [54]. Excess calories can contribute to fat synthesis and the 
accumulation of fat in the liver [53].  
Table 1. Overview of some nutrient requirements in childhood liver disease. Modified 
table from [51] and [54].  
Nutrient Daily requirement  Comments 
Energy  < 12 months up to 150% of EER  
> 12 months up to 120-170% of EER 
Check weight, MUAC 
and growth percentiles 
to secure energy needs 
Protein  2-4 g/kg  Avoid protein restriction 
Fat 30-60% of total energy 
MCT  30-70% of total fat Increase MCT 
percentage by 
decreasing bile flow. 
EFA  5-11% energy as linoleic acid 
Carbohydrates  40-60% of total energy 
Vitamin A  < 10 kg 1 500 μg/day  
>10 kg start with 3000 μg/day  
300 μg/kg/day up to 7 500 μg of orally 
available water miscible preparations.  
Adjust supplements to 
keep serum levels 
within reference 
ranges.  Higher single 
dose of vitamins A and 
D may be used in 
refractory deficiency  
Vitamin D, 
cholecalciferol  
<40 kg 3-5 μg/kg  
>40 kg 75-125 μg/day 
Vitamin E, Į-
tocopherol  
7-134 mg/kg/day 
Vitamin K  2 mg /kg weekly Monitor INR 
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Water soluble 
vitamins  
Double nutrient reference values   
Calcium  25-100 mg/kg/day  Supplement as needed  
Selenium  1-2 μg/kg/day  Weekly until repletion is 
achieved  
Sodium  Minimum 1 mmol/day  Consider salt 
restrictions in older 
children  
Zinc  1 mg/kg/day  Weekly until repletion is 
achieved  
 
Estimated energy requirement (EER), mid-upper arm circumference (MUAC), medium chain 
triglycerides (MCT), essentially fatty acids (EFA), international normalised ratio (INR).  
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3 Lymphoedema 
The lymphatic system consists of the lymph, lymphatic vessels, lymph nodes, spleen 
and thymus, as shown in Figure 3. The key functions of the lymphatic system include 
regulating tissue fluid volume, transporting fats absorbed from the intestines, and 
priming the immune system against infections by carrying material to local lymph 
nodes [56].  
General peripheral lymphoedema occurs due to a structurally or functionally 
defective lymphatic system (lymph vessels and/ or lymph nodes) and is a chronic 
condition [57-59]. Lymphoedema should not be confused with oedema, which has a 
systemic cause. Oedema is a clinical term in which fluids, particularly interstitial fluids 
gather and accumulate beneath the skin. 
Oedema is generally not a permanent 
issue and can be treated [60].  
Interstitial fluid pressure is determined by 
a complex interplay between the fluid 
influx (blood capillary filtration), the fluid 
outflow (venous reabsorption, lymph flow), 
and the compartment’s ability to expand 
(tissue compliance) [61]. Capillary filtration 
pressures and interstitial colloid osmotic 
pressures support transmembrane flux 
from the capillary into the interstitium, 
whereas interstitial fluid pressures and 
intra-capillary colloid osmotic pressures 
lead to fluid reabsorption. Venous 
capillaries reabsorb 90% of the fluid that 
enters the interstitium by normal capillary 
filtration. Interstitial fluid homeostasis is 
balanced by lymph fluid formation in the 
initial lymphatic vessels.  
Figure 3. The lymphatic system. 
Reprinted with permission from Encyclopædia 
Britannica Web.11 Jun.2014 
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The following three mechanisms have been suggested for the uptake of interstitial 
fluid into the initial lymphatics: vesicular transport, osmotic pressure gradients, and 
fluid pressure gradients. It is generally accepted that interstitial fluid pressure is the 
main determinant of initial lymph filling and lymph flow [62]. The lymphatic vessels 
collect lymph (proteins, wastes, water, and fats) from cells in the body and carry the 
lymph to the lymph nodes. The lymph nodes filter the waste materials and then return 
the lymph to the blood stream [63]. If dysfunction or obstruction occurs in the 
lymphatic system, lymphatic stasis occurs, permitting the accumulation of protein-rich 
fluid within the interstitium. The increased protein concentration leads to increased 
tissue colloid osmotic pressure, which drives fluid into the interstitium and causes 
oedema and the clinical manifestation of lymphoedema.  
 
Figure 4. Lymphoedema in the foot of a 4-year-old patient with LCS1. 
(Reprinted with permission from O Aagenaes). 
 
 
Lymphoedema develops only over prolonged periods of time due to the body’s 
capability to compensate. Initially the tissue is soft but will harden if the 
lymphoedema is not treated. The accumulation of fluid results in the growth of 
connective tissue. If the swelling persists for an extended period, an inflammatory 
response develops in the subcutaneous tissues causing tissue fibrosis (scar tissue) 
in the oedematous area. Fibrosis can be reversed only to a small extent [58, 63]. 
Lymphoedema is therefore generally progressive and can vary from a mild to a 
painful disabling and disfiguring condition [64]. When the lymphoedema worsens, the 
skin becomes less resistant to infections. Swollen skin chaps more easily and 
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permits the entry of bacteria leading to inflammation, erysipelas or cellulitis [65, 66]. 
Even a small scratch or an insect bite can cause long-lasting inflammation [67]. 
However, early diagnosis and treatment may prevent serious progression of the 
disease e.g. marked disfigurement and physical disability [68]. Lymphoedema is 
generally not life-threatening, but serious complications may occur especially due to 
the risk of infections [69-71].  
Lymphoedema is divided into a primary and secondary form. Primary lymphoedema 
results from genetic damage, whereas secondary (acquired) lymphoedema is a 
consequence of lymphatic failure resulting from trauma, surgery, radiotherapy, or 
parasitic infection [72, 73]. The clinical manifestations of secondary lymphoedema 
typically involve a single limb, whereas more widespread involvement of the body 
may be observed in primary lymphoedema [74]. 
Studies of the prevalence of lymphoedema are limited. Worldwide secondary 
lymphoedema is the most prevalent form, representing approximately 80% [75]. One 
of the most prominent causes of lymphoedema is the lymphatic filariasis which 
mainly affects people in southeast Asia (65%) and Africa (30%). The WHO estimates 
that more than 120 million people are currently infected with the parasite, and 
approximately 40 million are disfigured and incapacitated by the disease [73, 76]. In 
industrialised countries, cancer therapy is the leading cause of secondary 
lymphoedema. In the US, it has been estimated that given a 20% incidence of 
lymphoedema after cancer treatment it yields a potential 1.36 million cases of 
lymphoedema.It is estimated that 2 - 3 million people suffer from lymphoedema in the 
US [77]. In the UK, it is estimated that 100 000 persons suffer from lymphoedema 
[78]. In Norway, the prevalence of lymphoedema has been estimated at 
approximately 7 000 persons, but this number likely represents an underestimation 
[79].  
3.1 Primary lymphoedema 
Primary lymphoedemas are rare disorders and are manifestations of a lymphatic 
malformation developing during the later stage of lymphangiogenesis. Primary 
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lymphoedema also includes other types of lymphoedema without an identifiable 
aetiology, e.g., infection. Primary lymphoedema has also been considered congenital 
because the great majority of cases are caused by a congenital defect in the lymph 
transportation system, including the lymphatic channels and the nodes (i.e., aplasia, 
hypoplasia, or hyperplasia) [80]. Hereditary lymphoedema tends to involve one or 
both lower extremities but can also involve the upper extremities or even the face 
[81]. Some hereditary syndromes in which lymphoedema dominates the clinical 
picture are summarised in the article of Schulte-Merker et al. [82]. The best-known 
hereditary lymphoedema is Milroy disease (hereditary lymphoedema type I) [83]. The 
prevalence of primary lymphoedema is approximately 1.15 per 100 000 for 
individuals younger than 20 years of age [84]. Prevalence estimates for congenital 
lymphoedema are approximately 1 case per 6000 to 10 000 live births [77].  
 
3.2 Genetics of lymphoedema 
Numerous genetic diseases are associated with lymphoedema [85]. Approximately 
nine known causal mutations for inherited human lymphoedema have been reported 
[57, 86]. 
It is unclear whether the variable age of onset for hereditary lymphoedema is caused 
by locus and allelic heterogeneity or by genetic or environmental modifiers [87, 88]. 
Furthermore, the mechanisms that regulate lymph vessel remodelling and 
development are not fully understood [89]. However, two potentially associated 
genes, fms-related tyrosine kinase 4 (FLT4) and forkhead transcription factor 2 
(FOXC2), have been identified. FLT4 encodes for the protein vascular endothelial 
growth factor receptor-3 (VEGFR-3). VEGFR-3 plays an important role in lymphatic 
development and regulates the development and maintenance of the lymphatic 
system [90]. FOXC2 controls the later steps of lymphatic vascular development [89]. 
The collagen- and calcium-binding EGF domain-containing protein 1 (CCBE1) has 
recently been described as essential for lymphangiogenesis [91]. 
Mutations in the FLT4 gene cause Milroy disease, and FOXC2 may contribute to 
lymphatic dysfunction in lymphoedema-distichiasis syndrome [57, 92]. Milroy disease 
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is transferred as an autosomal dominant trait [93]. Hennekam lymphangiectasia-
lymphoedema syndrome is an autosomal recessive disease associated with 
mutations in the CCBE1 gene [94, 95]. 
 
3.3 Diagnosing lymphoedema 
The absence of a valid and accepted definition for the presence of lymphoedema and 
a lack of awareness of the condition decrease the likelihood of early diagnosis [57], 
and early treatments are therefore often hampered [77]. A recent study by Blome et 
al. stated that an average of 13.5 years passed from the appearance of the first 
symptoms to the start of complex decongestive therapy (CDT) treatment in patients 
with primary leg lymphoedema [68].  
Different approaches for the clinical description of lymphoedema have been 
proposed. In 1957, lymphoedema was described as primary or secondary [96]. Later, 
primary lymphoedema was divided into three categories classified by age at onset: 
congenital, praecox, or tarda [75, 97]. Congenital lymphoedemas present within 
approximately 2 years of birth. Lymphoedema praecox presents between 2 and 35 
years of age but typically becomes clinically apparent at or near puberty. The 
praecox type is the most common form of primary lymphoedema. Primary 
lymphedoema tarda is considered to be inherent with delayed manifestations and 
has a late onset (after 35 years of age) [98]. This terminology is imprecise, thereby 
making classification problematic [99]. 
The International Society of Lymphology has attempted to unify the broad range of 
worldwide diagnostic and treatment protocols for peripheral lymphoedema into a 
Diagnosis and Treatment of Peripheral Lymphoedema Consensus Document that 
represents a consensus among the international community [100]. However, given 
the lack of hard data, the fact that no treatment method has undergone any 
satisfactory meta-analysis, and the current lack of agreement regarding the clinical 
evaluation of lymphoedema, this document is not commonly used worldwide [100]. In 
addition, no unified method of lymphoedema classification has yet achieved 
consensus [100]. The large number of different classifications of lymphoedema and 
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inadequate or causal descriptions of lymphoedema make it impossible to evaluate 
and compare therapeutic results among different treatment centres [101, 102]. This 
inability represents a serious worldwide problem in assessing how best to prevent 
and treat this disabling disease [101]. Today, as causal genes are identified, there is 
the possibility of creating a classification based on patient phenotypes and known 
genetic aetiologies [57]. 
As mentioned above, the classification systems for diagnosing lymphoedema vary 
but are generally determined by a patient’s clinical history and physical examination 
[100]. Lymphoedema can be confirmed with lymphoscintigraphy, computed 
tomography, magnetic resonance imaging, or (duplex) ultrasound [102]. The 
lymphatic anatomy is demonstrated with lymphoscintigraphy [103].  
The common differential diagnoses in Western patients with lower limb swelling 
include secondary lymphoedema, venous disease, lipoedema, and adverse reactions 
to limb surgery [103]. Furthermore, comorbid conditions, such as congestive heart 
failure, hypertension, and cerebrovascular disease, including stroke, might influence 
the therapeutic approach taken [100]. Complications of chronic lymphoedema include 
recurrent episodes of erysipelas, superficial lymphangiectases, verrucous 
lymphoedema (papillomatosis lymphostatica), and angiosarcoma, which is often 
multifactorial [75]. Erysipelas is commonly observed in conjunction with 
lymphoedema and complicates or might aggravate the condition [104]. 
 
3.4 Treatment 
The main aims of treating lymphoedema are to prevent the progression of disease, to 
achieve mechanical reduction and maintenance of limb size, to alleviate the 
symptoms that arise from lymphoedema, and to prevent skin infections (erysipelas/ 
cellulitis/lymphangitis) [105]. The treatment of lymphoedema is divided into 
conservative (non-operative), pharmacological, and operative methods [100]. 
Conservative treatment  
20 
 
Lymphoedema is primarily treated with CDT, which is also known as complete 
decongestive physiotherapy (CDP) or combined physical therapy (CPT) [100, 103, 
106]. For mild lymphoedema, elevation of the affected limb(s) and skin care 
(cleansing and low pH lotions and emollients) are important for successful treatment 
[100]. 
CDT involves a two-stage treatment program that can be used in both children and 
adults. The first phase consists of skin care, a specific light manual massage referred 
to as manual lymph drainage (MLD), range of motion exercises and compression 
which is typically applied with a multi-layered bandage-wrapping to enhance 
lymphatic drainage. Phase 2, initiated promptly after Phase 1, aims to conserve and 
optimise the results of Phase 1. Phase 2 consists of compression by a low-stretch 
elastic stocking or sleeve, skin care, continued remedial exercise, and repeated MLD 
as needed [100, 106, 107]. Such a treatment significantly reduces the extent of 
lymphoedema and microlymphatic hypertension, paralleled with a considerable 
decrease in the mean circumference of the limb [103]. In Norway, CDT has been 
available since the mid-1980s [79]. 
 
Pneumatic pumps are another form of compression massage. After pneumo- 
massage, form-fitting low-stretch elastic stockings or sleeves are used to maintain 
the reduction in lymphoedema [100, 108]. Typically a combination of the CDT and 
pneumatic pump methods is used to achieve optimal benefits. Heat therapy with hot 
water immersion, microwave, or electromagnetic irradiation has also produced some 
benefit for lymphoedema [100].  
Medical treatment  
Benzopyrones have demonstrated effectiveness in the treatment of lymphoedema by 
reducing oedema fluid, increasing the softness of the limbs, and decreasing elevated 
skin temperature [103]. However, benzopyrones (e.g., coumarin) can be hepatotoxic 
and therefore are not used in several countries [103]. Benzopyrones are not an 
alternative for CDT, and the usefulness of such medication has not yet been 
definitively determined [100].  
21 
 
The use of diuretics specifically for lymphoedema treatment is discouraged [100]. 
Fungal infections are treated with antimycotic drugs. Prophylactic administration of 
antibiotics to reduce erysipelas/cellulitis is recommended [100].  
Surgical treatment 
Surgical treatment can be categorised into physiological methods (flap interposition, 
lymph node transfers, lymphatic bypass procedures) reductive techniques such as 
debulking operations (direct excision or liposuction to remove fibro-fatty tissue), and 
prophylactic surgery [103, 109]. Very few prospective or controlled studies have been 
performed regarding surgical interventions, making it difficult to draw conclusions 
about the efficacy of various treatment options, and there is no consensus for 
surgical intervention, the type of procedures that are performed, or the timing of the 
intervention [109]. Some authors believe that surgical intervention should be 
reserved exclusively for patients who fail conservative treatments [103, 109]. 
Dietary treatment 
In chylous reflux syndromes (e.g. intestinal lymphangiectasia), a diet low in 
triglycerides with long-chain fatty acids and high in triglycerides with medium and 
short-chain fatty acids is of benefit especially in children. Otherwise, no special diet 
has proved to be of therapeutic value for uncomplicated peripheral lymphoedema 
[22]. In obese patients, a reduction in calorie intake combined with an exercise 
program may decrease limb bulk [100].  
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4 LCS1  
The clinical features of LCS1 include intrahepatic cholestasis in infancy and 
childhood, with recurrent periods in adolescence and adulthood and the progression 
of lymphoedema throughout childhood and adulthood. Both the severity of the 
cholestasis and/ or the frequency of recurrent cholestatic periods can vary 
considerably among individual patients. No other anomalies than cholestasis and 
lymphoedema have been described, and mental and motor development proceeds 
normally [9].  
The major concern in LCS1 in infancy and childhood is cholestatic liver disease that 
may lead to EDSL and the need for liver transplantation. Since 1996, six Norwegian 
patients have undergone transplantation in early childhood, and the most recent child 
with LCS1 who died of liver cirrhosis died in 1991 [110].  
The mortality in this patient group was high prior to 1970, when adequate nutritional 
support was not in regular use [111]. The introduction of routine vitamin K injections 
in approximately 1940 altered the prognosis of this disease by reducing the neonatal 
mortality [9]. Of 21 patients born before 1970, 11 died in early childhood [111]. The 
high mortality rates during this period are partly responsible for the young patient 
population observed in Norway at present. Severe growth retardation, rickets and 
peripheral neuropathy were frequent until adequate infant formula and vitamin 
supplementation were provided [111]. If cholestasis during infancy and childhood 
goes into remission, the liver disease generally remains quite stable, despite 
recurrent cholestatic periods. Only one patient has died of cirrhosis and 
hepatocellular carcinoma in adulthood [111], (Figure 5).  
Patients with LCS1 may require different actions from kindergarten, school or work, 
especially in connection with cholestatic periods. Patients’ abilities to concentrate in 
these periods may decline because of itching or sleepiness, hence reducing the 
capacity to learn or work. As lymphoedema is chronic and requires daily follow-up, 
adjusted physical activity may be considered. Vocational guidance is advised.  
As of June 2014 the total number of patients diagnosed with this syndrome worldwide 
is approximately 100, of whom 48 were diagnosed in Norway. Many of the Norwegian 
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Poland (4), Czech Republic (1), Bulgaria (3), Austria (1), Greece (4), Italy (2), Egypt 
(2), Iraq (3), the US (15) (Minnesota (11) and Chicago (4)), and Australia (1) [110]. 
Some of these patients have died.  
Several articles have been published, but knowledge of the adult patients as a group 
is scarce due to the small number of patients and the short time period which 
adequate treatment has been available to permit a normal lifespan. The oldest patient 
in Norway currently is 70 years old, and is the longest-surviving member of this patient 
group. The published articles on LCS1 in Norway are largely those written by 
Aagenaes (et al.) [10, 111, 113-116] or researchers from other regions of the world 
[117-123].  
 
4.1 Cholestasis and lymphoedema in LCS1 
Cholestasis 
Cholestasis is recognised shortly after birth and persists until 1 year or even 6 - 7 
years or more with varying severity in different patients [9, 113]. The histological 
picture of liver biopsies in infants is giant cell-transformation with intracytoplasmic 
pigment retention, and a slight increase in connective tissue in the periportal tracts 
and around the central veins [113]. In the adult cases, intracanalicular cholestasis 
with few multinucleated or giant cells has been identified [9] with variable degrees of 
increased connective tissue [113]. Liver histology findings do not demonstrate 
progression to fibrosis, and signs of portal hypertension are absent [9]. Laboratory 
examinations during cholestatic periods demonstrated hyperbilirubinaemia (primarily 
conjugated bilirubin), increased transaminases and ALP, hyperlipaemia, increased 
pre-ȕ (VLDL) and ȕ-lipoproteins (LDL), a slight decrease in albumin, and an increase 
in Į2-globulin [9]. Examinations of serum lipids during the cholestatic periods have 
demonstrated hyperlipaemia with elevated triglycerides, cholesterol and 
phospholipids [9]. In cholestatic periods, ALP is always increased [9]. Serum copper 
increases during cholestatic periods [9]. During cholestatic periods, all patients 
exhibit hepatomegaly, abnormal liver function, and severe malabsorption.  
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In infancy, jaundice is normally observed within the first 2 - 4 weeks after birth [111]. 
The serum bilirubin concentration is markedly increased in the first months, with a 
decrease into the normal range at age 3 - 4 years. At high levels of bile acids (> 40 
μmol/L), itching starts and often persists as a problem from approximately 6 months 
of age. The increased bile acids in infancy decrease slowly until the age of about 6 
years when they remain moderately elevated [111]. The liver enzymes ALT and AST 
increase, but only moderately increased at 2 - 3 years of age. Moderate elevations of 
Ȗ-GT, approximately twice the upper normal level, are observed in this syndrome, 
and the use of Fenemal (phenobarbital) increases this enzyme substantially in LCS1 
patients [111].  
Typically cholestasis eases during the first 1 - 2 years of life but may reoccur over 
irregular intervals. A long cholestatic period in the first 2 - 3 years of life can cause 
liver failure leading to death or the need for liver transplantation [111]. Most patients 
have a benign course of liver disease in adulthood [110], although some patients 
may suffer slowly progressive cirrhosis throughout adulthood [111]. 
 
The mean birth weight in patients with LCS1 is normal [9, 111]; the infants exhibit a 
normal appetite, but are characterised by having large amounts of pale, fatty stools 
and dark urine [9]. When cholestasis is diagnosed dietary treatment should begin 
with a high-energy and low-fat diet and supplemented with MCT-fat, fat-soluble 
vitamins, vitamins in general, and medication.  
Bleeding tendencies, rickets, anaemia, and growth retardation have been ascribed to 
malabsorption caused by the cholestasis. The bleeding tendency observed in the first 
patients described, was likely due to malabsorption rather than the liver disease per 
se [9]. No deaths from haemorrhage have occurred since vitamin K substitution was 
regularly instituted [9].  
 
The severity and length of recurrent periods vary among individuals, but most last for 
2 - 6 months (range 2 weeks to approximately 1 year) [111]. One or more cholestatic 
periods are usually observed in puberty and often in pregnancy [111]. Cholestasis 
may therefore be triggered by hormonal changes [124, 125]. Infections, trauma or 
operations may also be followed by a cholestatic period [111]. During cholestatic 
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periods in adolescence and adulthood patients may need medical and nutritional 
care, resembling what they received as children and what is often needed for 
cholestasis. The need for medical and nutritional follow-up in these periods depends 
upon the severity of the cholestasis and its duration. Some of the patients miss up to 
6 months to a year of school due to cholestatic periods. Three men have experienced 
no cholestatic periods after reaching adulthood [111].  
Lymphoedema 
Lymphangiography has demonstrated hypoplasia of the lymphatics, collateral filling 
with dermal backflow, and retarded emptying of contrast from the lymphatics [114]. 
Approximately half of patients develop lymphoedema before 6 - 7 years of age, and 
the other half do so before puberty [111].  
 
Before CDT treatment 
 
After CDT treatment 
 
Before CDT treatment was 
available 
Figure 6. Lymphoedema in an adult patient with LCS1 before and after 2 weeks of 
CDT treatment and in a 4-year-old patient before CDT treatment was available. 
(Reprinted with permission from K Vik and O Aagenaes).  
 
The lymphoedema primarily affects the lower extremities, but the hands, arms, 
periorbital soft tissue, thorax, and small intestine can also be affected [110, 111].  
Lymphoedema can have quite severe social implications, especially for women with 
LCS1, and recurrent erysipelas has been a problem for many of the patients [111]. 
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Lymphoedema was the reason for obtaining disability pension in four of the nine 
adults evaluated in 1998 [111]. 
4.2 Genetics in LCS1 
LCS1 exhibits an autosomal recessive inheritance pattern, and the genetic cause is 
assumed to have originated in the long arm of chromosome 15q [112, 126]. The 
exact genetic mutation in LCS1 remains unknown [110, 127]. There is a considerable 
interfamilial and intrafamilial variation within LCS1, as is often observed in rare 
diseases [93, 126, 128, 129].  
Some have suggested a biological connection between lymphatic and hepatic 
function in lymphoedema cholestasis syndromes (LCS) [111, 114, 127]. The 
hypothesis is that mutations causing LCSs act primarily upon the lymphatic system, 
and in some patients the liver is especially vulnerable to deleterious consequences of 
deranged lymphatic function, thus resulting in cholestasis. The lymphoedema and 
cholestasis manifested in LCSs are therefore expected by some to share a single 
underlying aetiology; however given that the CCBE1 mutation has been found in only 
one LCS patient to date, a mutation in another, unidentified gene cannot be excluded 
as the underlying cause of the cholestasis [110, 127].  
 
4.3 Diagnosing LCS1 
Neonatal cholestasis has many different causes [22]. If the child does not have any 
relatives with LCS1 or ancestors from south-western Norway, it can be difficult to 
reach a correct diagnosis before the lymphoedema develops. Regardless, to 
establish the diagnosis of LCS1, cholestasis must be present in the first year of life, 
and lymphoedema must be identified at that time or later. Ancestors from south-
western Norway, relatives diagnosed with LCS1, blood tests, or biopsies of the liver 
are not sufficient to make the correct diagnosis.  
Lymphoedema is diagnosed clinically. Diagnosing the early signs of lymphoedema is 
difficult and often causes late initiation of CDT in patients with LCS1. The last patient 
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diagnosed with LCS1 in Norway was nearly 40 years old before finally receiving the 
correct diagnosis in 2012; by that time, the patient had developed extensive 
lymphoedema. Five patients with LCS1 have been mistakenly diagnosed with biliary 
atresia, but when surgically explored, the biliary tree was normal [111]. The correct 
diagnosis was then not established until lymphoedema appeared. Today, advanced 
techniques for exploring the biliary tree have rendered such operations unnecessary. 
There are several differential diagnoses for isolated cholestasis or lymphoedema as 
described in sections 2.3 and 3.3, respectively. However, LCS1 is the only known 
hereditary lymphoedema that is associated with cholestasis [118]. 
4.3.1 Treatment of LCS1 
The same treatments for patients with cholestasis or lymphoedema, due to other 
causes (as described in section 2.4 and 3.4) can be used in patients with LCS1.  
It should be specifically noted that LCS1 patients born after 1970 have clearly 
superior outcomes to those born between 1945 and 1970. The dietary treatment for 
LCS1 patients after 1970 was infant formula including MCT (Pregistimil) after 
weaning until malabsorption was no longer present, supplementation with vitamins A, 
B, C, D, E and K, and medication with cholestyramine (Questran) (8 - 16 g/day), and 
phenobarbital (Fenemal) (3 - 5 mg/kg/day) [111]. The improvement observed in the 
infants and children was primarily due to the introduction of infant formula with MCT 
and the use and monitoring of fat-soluble vitamin supplements [111]. This nutritional 
improvement has prevented severe rickets, neuropathy and bleeding and improved 
growth in children [111]. Itching was kept relatively moderate by the use of 
cholestyramine and/ or phenobarbital.  
Today the physicians and dieticians at OUS, Rikshospitalet recommend the following 
regimen for children with cholestasis (including patients with LCS1): supplementation 
with fat-soluble vitamins, including vitamins K1 (Ka-vit liquid (20 mg/ml) 2 mg p.o.), A 
and D (Ketovite liquid 5 ml x 2 p.o.); multivitamins (Ketovite tbl, 1 x 3 p.o.); and a 
vitamin E mixture ((50 mg/ml) 100 mg x 1) [130]. In addition a reduced-fat diet is 
recommended in which 50% of the fat intake is from MCT; however, the quantity of 
MCT used depends upon the nutritional status of the infant. If the infants are 
breastfed the mothers are advised to nurse the baby at each mealtime with the first 
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milk that contains less fat and thereafter substitute with infant formulas such as 
Caprilon (75% MCT), Pregestimil (54% MCT) or Nutramigen (55% MCT). Medication 
may include ursodeoxycholic acid (Ursofalk), rifampicin (Rimactan) and 
cholestyramine (Questran). 
Some of the patients have undergone plastic surgery for elephantiasis due to 
unsatisfactory treatment of lymphoedema [9, 114]; therefore, lymphoedema must be 
treated as soon as it is identified. The severity of lymphoedema has improved 
substantially, especially after 1985, when CDT became available in Norway [111]. As 
in other lymphoedematous diseases, antibiotics may be used to prevent erysipelas.  
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5 Diet and health 
It is generally accepted that nutrition has major effects on health throughout life [131-
133]. The role of dietary factors in the development of chronic disease are particularly 
evident [134]. Dietary recommendations or dietary reference values (DRV) are 
therefore provided by health authorities to promote health and prevent lifestyle-
related diseases, and reduce the risk factors for such diseases [135]. The 
recommendations form the basis of the national nutrition policy, education, and 
consumer materials for the general public and for specific groups, industry, nutrition 
educators and health professionals treating specific diseases. Nutritional 
recommendations must be based on current scientific and medical knowledge and 
are therefore regularly updated [136].  
To assess and evaluate the complex relationships between diet and specific health 
outcomes accurate and consistent measurements of dietary intake and patterns of 
eating are crucial [137, 138]. Several measurement methods have been developed to 
quantify the amount of certain substances eaten and to compare dietary intake with 
current recommendations [139, 140].  
 
5.1 Dietary assessment challenges 
Several challenges are involved in choosing the best method of dietary assessment, 
depending on the objectives of the study, the type of information required, the 
available resources and the population of interest [141]. The primary goal of 
nutritional assessment is to identify nutritional risk factors that influence morbidity or 
mortality and that may be modifiable. 
The data required both in larger epidemiological health surveys and for individuals 
are potentially subject to many sources of both random and systematic error [142]. 
The different methods that can be used have both advantages and limitations, and 
none of the methods are entirely satisfactory [142, 143].  
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The data also rely on the accuracy of reports of current or habitual food intake by the 
study participants; physical and psychological characteristics of the study participants 
therefore play a significant role in acquiring data [144]. One of the most common 
errors is under-reporting. In instances in which the subjects themselves report their 
energy intake (EI), the EI is generally under-reported compared with energy 
expenditure [145]. This discrepancy makes it more difficult to identify individuals or 
populations who suffer nutritional deficits.  
 
5.2 Dietary assessment methods  
Dietary assessment methods allow for a determination of the macronutrient (energy, 
proteins, fats, carbohydrates) and/ or micronutrient (vitamins, minerals) intake of a 
given individual or population. Measurements of body composition and energy 
expenditure add supplemental information to support the nutritional advice given for 
the individual or population of concern.  
Dietary assessment methods used for evaluating individual food consumption can be 
classified as prospective or retrospective methods. The three most common methods 
used to assess dietary intake are food frequency questionnaires (FFQ), diet records 
(weighted or estimated), and 24-hour recall [146]. Diet records and weighed food 
records are prospective methods, whereas food frequency questionnaires and 24-
hour recall are retrospective methods.  
The advantages of prospective methods are as follows; they are not affected by 
recall bias; intake is quantified; they provide information about typical meal and food 
patterns; and portion size estimates are more accurate than retrospective methods. 
Disadvantages include a high subject burden and a high drop-out rate, generally no 
more than a week of data recording is possible. Furthermore monitoring can alter 
eating behaviours (the manner of eating or eating different type of foods), and 
multiple data collections are required over several months to capture habitual intake 
[147].  
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Retrospective methods are simple and inexpensive, and do not affect food habits. 
These methods can be used on a large scale and can last up to one year. The 
disadvantages of retrospective methods are the reliance on the subject’s memory 
and his or her ability to estimate portion sizes, recall food preparation methods, and 
remember food composition.  
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6 Aims 
The overall aim of this research project was to obtain new evidence-based 
knowledge about the progression of liver disease in a group of adolescent and adult 
patients with LCS1 over a period of nine years, to evaluate the need for the improved 
treatment and follow-up of liver disease in the absence of cholestasis and/or in 
relation to lymphoedema.  
 
The specific aims were as follows:  
- To investigate the prognosis of patients with LCS1 and to assess biochemical 
liver markers compared with healthy controls (paper I).  
- To evaluate the diet of patients with LCS1 compared with healthy controls and 
the general Norwegian population (paper II).  
- To describe lymphoedema in adult patients with LCS1 (paper III). 
-  To evaluate dietary intake, nutritional status and the progression of liver 
disease over nine years of follow-up (paper IV). 
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7 Subjects and methods 
This thesis was based on observational data acquired from two case-control studies 
performed cross-sectionally, nine years apart. Patients with LCS1 and their 
respective controls were evaluated from late autumn (October/ November) of the 
starting year until early spring (February) of the following year, both in 2000/2001 and 
2009/2010. The first study (papers I and II) was performed as part of a Master’s 
Degree. The second study in 2009/2010 (papers III and IV) was planned as a follow-
up of the first study to evaluate the progression of liver disease and to explore other 
aspects of LCS1. To keep the data measurement methods as consistent as possible 
between the two studies, the same methodology for dietary intake and biochemical 
evaluation that was used in the first study was also used in the follow-up study.  
 
7.1 Subjects 
7.1.1 Subjects 2000/2001 
All known patients in Norway who have been diagnosed with LCS1 were invited to 
participate in the study (two patients were not asked; one was intentionally excluded 
because of geographical distance, and the second was forgotten due to 
misunderstandings). Names and addresses for the written invitations were provided 
by the “Interest group for Aagenaes syndrome” and by O Aagenaes. One 
informational meeting about the study was held in the summer of 2000 by M Drivdal 
and O Aagenaes near Lyngdal, close to where most of the patients lived.  
Of 23 available patients, sixteen (seven females and nine males) provided written 
consent. Parents of three participants between 10 and 17 years of age gave consent 
on behalf of their children to participate in the study; consent was also given by the 
patients themselves. Patients or parents who declined participation include three 
children who were under ten years of age and two adolescents who cited personal 
reasons and the large volume of blood required.  
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Five healthy sex-, age- and residential area (council)-matched controls for each study 
subject were randomly drawn from the National Registry of Norway. Each of these 
control persons were telephoned individually, and the first person who agreed to 
participate in the study was included as the control person. For one patient, none of 
the five controls were willing to participate; therefore, one control person from 
another patient was included.  
7.1.2 Subjects 2009/2010 
In 2009/2010, all of the patients who had taken part in the first study were over 18 
years of age; therefore, only patients above 18 years of age with LCS1 were invited 
to participate in this study. A total of 20 patients were invited.  
Eighteen patients provided written consent, and 17 (eight females and nine males) 
were finally included. Both the patient who first gave consent as well as the two other 
patients who did not participate, refused due to geographical distance or personal 
reasons. To recruit controls, information about the study was displayed on notice 
boards in hospitals and at the University of Oslo. One control person for each patient, 
matched by birth year (+/- 1 year) and sex was recruited among the employees of 
Lovisenberg Deaconess Hospital, Oslo University Hospital, students from the 
University of Oslo, or friends of students and employees. 
 
7.2 Methods 
7.2.1 Case-control design 
Due to the heterogeneity of the patient group with respect to age and gender, it was 
considered important to establish a control group that was similar in some aspects 
(age, gender) to compare different biochemical and nutritional parameters. 
Additionally case-control studies are commonly used for initial, inexpensive 
evaluation of risk factors and are particularly useful for rare conditions [148]. 
Furthermore, the case-control design was chosen because such studies can 
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determine if there is an association between the condition (e.g., nutritional status) 
and the risk factor (e.g., diagnosis of LCS1).  
7.2.2 Methods 2000/2001 
All of the data were obtained in or near the participants’ home living area, and all 
contact during the study period between the study participants and the project 
manager (M Drivdal) was conducted through phone and postal mail. All participants 
received a package that contained information about the proceedings of the study, a 
scale, a log book for dietary records, information about the blood samples, and a 
prepaid address sticker for the return of the scale and log book.  
Food records 
A 4-day weighed record was chosen to estimate the group means of micro- and 
macronutrient intake and current individual intake of macronutrients and energy. 
Dietary fat intake was of particular interest due to the cholestasis and recurrent 
cholestatic periods. A weighed record was chosen because it is considered a more 
accurate measure of dietary fat intake than a 24 h recall or an FFQ [142]. The single 
weighed record was also chosen given limited financial resources. The participants 
recorded their food intake for 4 consecutive days (3 week days and one weekend 
day). Phillips digital scales with a precision of +/- 1 gram and a maximum capacity of 
2500 grams were used. Written information, scales and a logbook were sent to the 
participants by post. All participants were contacted by phone (by M Drivdal) on the 
second day of registration to encourage completion of the registration and to answer 
questions from participants regarding the dietary recording.  
All food records were returned by the participants and checked and coded by the 
same person (M Drivdal) before statistical calculations were performed. The 
registered intake of food and supplements was computed using the food database 
AKF96, which is based on the 1995 Norwegian food composition table, and the food 
calculating system BEREGN [149]. The contributions of vitamins A, D and E from 
medical supplements (Ketovite, Kanavit, Multibionta) were not included in the 
database; these were therefore calculated manually and added to the registered 
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intake before the statistical analysis. As no food database existed for vitamin K at the 
time of the study, the intake of this vitamin could not be evaluated from the diet 
registration. In the AKF96 food database energy from fibre was not included.  
A telephone interview about food habits and general food consumption was also 
conducted. This interview also included questions about other topics, such as 
medications and smoking.  
The basal metabolic rate (BMR) was calculated for each participant based on 
equations for weight, height, sex and age [150]. Body weight (to the nearest 
kilogram) and height (to the nearest centimetre) were measured at home by the 
participants themselves and registered in the food logbook. To evaluate whether 
energy intake met energy requirements, the Goldberg cut-off was used to define 
under- or over-reporting [151, 152]. Cut-off value 1 evaluated whether the reported 
energy intake was representative of the usual intake, and cut-off value 2 evaluated 
whether the reported intake was a probable measure of the food consumed during 
the actual dietary registration of concern.  
Biochemical analyses 
Fasting venous blood samples from the participants were drawn at the nearest local 
hospital laboratory located in Stavanger, Flekkefjord, Kristiansand or Oslo. The 
laboratory personnel at different sites were provided written and oral instructions 
about how to collect and store the samples. This information was prepared by a 
biochemist at OUS, Rikshospitalet and made available by M Drivdal. Haematologic 
indices were determined at these hospitals using standard methods due to the limited 
stability of the samples. The other samples were stored at −20°C for a maximum of 
10 weeks before transportation on dry ice and were subsequently stored at −70°C for 
four months before analysis at OUS, Rikshospitalet. Standard methods and 
equipment were used for general clinical biochemistry work (Hitachi 917; Roche, 
Basel, Switzerland; AutoDELFIA; Perkin Elmer, Boston, Mass., USA; Axsym; Abbott, 
Chicago, Ill., USA; and BN II; Dade Behring, Liederbach, Germany). Specific fatty 
acids in serum total lipids were analysed by gas chromatography using  SP-2340 
capillary columns (Supelco Inc., Bellefonte, PA, USA) using a Hewlett-Packard 
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5880A gas chromatograph (Avondale, PA, USA) [153]. Fat-soluble vitamins were 
protected from light and analysed at Vitas AS with an EDTA-reversed phase HPLC 
from electrochemical reduction followed by fluorometric detection with HP 1100 liquid 
chromatography (Agilent Technologies, Palo Alta, CA, USA).  
7.2.3 Methods 2009/2010 
The follow-up study was performed at the Centre for Rare Disorders in cooperation 
with the Resource Centre for Oral Health in rare medical conditions (TAKO-Centre) 
at the Lovisenberg Deaconess Hospital and in cooperation with the Department of 
Vascular Investigations, OUS, Aker. Except for the dietary records, all data acquired 
were obtained in Oslo at the Lovisenberg Deaconess Hospital and OUS, Aker. For 
patients who lived too far from Oslo for a day visit, overnight accommodations in 
Lovisenberg Deaconess Hospital´s guesthouse were provided.  
Additional evaluations not included in the 2000/2001 study were included in the 
follow-up study to evaluate the patients lymphoedema, oral health status, bone 
health and quality of life. The methods of assessing oral health status, bone health, 
and quality of life are not described in further detail here given that these data are not 
included in the thesis.  
Food records 
All patients received a scale and instructions for the dietary records by postal mail, 
and they were asked to complete this portion of the study before they met at 
Lovisenberg Deaconess Hospital for blood samples and other evaluations. The 
controls received the scales and the information about the food registration directly 
from M Drivdal before the other evaluations were performed. The dietary data were 
acquired and handled as described in section 7.2.2 with the exception of a few 
differences, which are described below.  
Energy and nutrient intake data from the food records were computed using KBS, a 
software system developed at the University of Oslo, Norway. Energy and nutrient 
values of the food items were based on the official Norwegian food composition 
database published in 2006 [154]. For the evaluation of dietary intake in the 
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2009/2010 study, the energy from fibre was included in the calculation of total 
consumed energy intake. This energy from fibre adds an 8 kJ higher energy level per 
gram of fibre, and was therefore corrected for in the dataset from 2000/2001 before 
the statistical analyses from baseline to follow-up were performed (in paper IV). The 
Goldberg cut-off was not used in this study because of the small sample size, and 
the lack of information about individual activity levels [155]. 
No interview about general food habits was performed, as in 2000/2001, instead 
each participant had a consultation with M Drivdal during which the dietary records 
were checked to eliminate possible misunderstandings regarding food registration 
and to include other relevant data that seemed to be missing e.g., information about 
dietary supplements, beverages, smoking or medication.  
Biochemical analyses 
All blood samples were drawn at the Lovisenberg Deaconess Hospital. Haematologic 
indices were determined at the hospital using standard methods due to the limited 
stability of the samples. Serum 25(OH)D levels were measured by 
radioimmunoassay (DiaSorin, Stillwater, MN, USA) at the Hormone Laboratory, OUS, 
Aker. The other samples were stored at −70°C for a maximum of 26 weeks before 
analysis at OUS, Rikshospitalet. Standard methods and equipment were used for 
general clinical and biochemical studies (Modular analytics SWA; Roche, Basel, 
Switzerland; AutoDELFIA; Perkin Elmer, Boston, Mass., USA; Axsym; Abbott, 
Chicago, Ill., USA; and BN II; Dade Behring, Liederbach, Germany). 
Evaluation of the lymphoedema 
An experienced physician at Department of Vascular Investigations, OUS, Aker, 
obtained data about lymphoedema in the LCS1 patients. A clinical history was 
obtained, including symptoms such as heaviness, asymmetric swelling and 
reductions in limb function caused by swelling, episodes of exudation and erysipelas, 
and the use of compression garments. These data were supplemented by 
information from a self-administered questionnaire with response categories that was 
designed to obtain information about patients’ experiences and their subjective 
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thoughts on living with lymphoedema. The questionnaire was designed for the LCS1 
patients in this study by M Drivdal and approved by O Aagenaes and CE Slagsvold 
(Appendix 1).  
The patients were asked to stop compression therapy (compression garment, CDT 
and pulsator use) four days prior to the clinical examination. The clinical examination 
included inspection, palpation, the estimation of dystrophic changes, and the 
evaluation of Stemmer’s sign (inability to pinch a skin fold at the base of the second 
toe or finger).  
In addition, all patients underwent air plethysmography and colour Duplex ultrasound 
scanning, because lymphoedema may cause changes in the subcutis, that manifest 
as subcutaneous hypoechoic layers visible on ultrasound. These hypoechoic layers 
or subcutaneous tissue changes, which are related to the distribution and extent of 
lymphoedema, were recorded and incorporated into the individual patient 
lymphoedema classification (paper III). The examinations for subcutaneous tissue 
oedema were performed using B-mode ultrasonography (General Electric Logiq E9 
colour duplex scanner with a 7 MHz linear array probe). 
Bio-Impedance Analyses 
A direct segmental multi-frequency bioimpedance analysis (DSM-BIA) was included 
to describe the extent of lymphoedema more thoroughly in each patient [156, 157]. 
The BIA measurements of participants were obtained after overnight fasting and 
were performed with patients in an upright position wearing light clothing. In BIA, an 
electric current is conducted along the path of least resistance in the body. This path 
represents the tissue with the highest water content. Most of the low-frequency 
current passes through extracellular water (ECW), including lymph. At higher 
frequencies, the current passes through both extra- and intracellular fluids. These 
data allow the evaluation of the oedema content of different body segments among 
LCS1 patients. The relevant body composition measurements for oedema evaluation 
include total body water (TBW) and ECW for the entire body as well as for five 
separate segments (four limbs and the trunk). The InBody 720 manufacturer defines 
an ECW:TBW ratio of > 0.40 as the presence of oedema. An oedema index > 0.40 
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was defined as lymphoedema in this work. The DSM-BIA measurements were 
performed using an InBody 720 Body Composition Analyzer, Biospace Co. Ltd, 
Seoul, Korea.  
7.2.4 Statistics  
Descriptive statistics are presented as median values (due to the vulnerability to 
extreme values in small samples), standard deviations, quartiles and ranges. Non-
parametric tests (the Wilcoxon sign rank sum test for related samples and the Mann-
Whitney U test for independent samples) were used to evaluate differences in 
dietary, biochemical and impedance measurements between patients and controls. 
Fisher’s exact test was used to evaluate categorical data. All of the reported p-values 
are based on two-sided tests with a significance level of 5%. The statistical analyses 
were performed using the Statistical Package for Social Sciences (SPSS, version 
18.0, SPSS, Inc., Chicago, USA). Confidence intervals were calculated using the 
Wilcoxon signed rank sum test for significant data (Minitab Statistical Software, 
Release 15 for Windows, State College, Pennsylvania, USA).  
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8 Summary of papers 
8.1 Paper I 
Prognosis, with evaluation of general biochemistry, of liver disease in 
lymphoedema cholestasis syndrome 1 (LCS1/Aagenaes syndrome) 
Introduction: In this paper, a clinical description of liver disease in Norwegian 
patients with LCS1 is presented.  
Results: Cirrhosis occurred in four patients born before 1990, and three subjects 
died in infancy or early childhood. One subject exhibited slow progression of cirrhosis 
and died in adulthood. Slowly progressing cirrhosis occurred in one additional patient 
who is currently alive. Two other patients were considered to be at moderate risk of 
developing cirrhosis. Three patients had undergone liver transplant due to cirrhosis in 
childhood. 
The biochemical values for aspartate amino transferase (AST), (P=0.055), alkaline 
phosphatase (ALP), (P=0.001), Ȗ-glutamyl transferase (Ȗ-GT), (P=0.002), and bile 
acids (P=0.045) were significantly elevated in the patient group compared with 
healthy controls, despite being near normal reference ranges, whereas total protein 
(P=0.008) and serum albumin levels (P=0.005) were significantly lower than in 
healthy controls.  
Conclusions: Compared with other types of hereditary neonatal cholestasis, 
patients with LCS1 exhibit a relatively good prognosis. More than 50% of patients 
with LCS1 can expect a normal life span.  
 
8.2 Paper II 
Do patients with lymphoedema cholestasis syndrome 1/Aagenaes syndrome 
need dietary counselling outside cholestatic episodes? 
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Introduction: In this paper, the need for dietary counselling outside cholestatic 
periods in fifteen patients with LCS1 was assessed. The patients’ diets were 
compared with healthy matched controls and the general Norwegian dietary 
recommendations.   
Results: The patients (n=15) exhibited diets similar to the diets of the healthy 
controls, except for a significantly lower intake of energy from total fat (P=0.040) and 
saturated fat (P=0.020). The patients met most of the dietary recommendations for 
macronutrients, except for saturated fat, monounsaturated fat, refined sugar and 
fibre. Supplements were needed to meet the micronutrient recommendations. The 
patient group exhibited a significantly lower serum level of Į-tocopherol (P=0.010) 
compared with the control group, and the serum 25-OH D level was below reference 
ranges.  
Conclusions: Patients with LCS1 could benefit from dietary counselling regarding fat 
quality, carbohydrate intake (including fibre), and individual needs for vitamins D and 
E. To ensure normal serum 25-OH D and Į-tocopherol levels, regular examinations 
to determine the need for supplementation with vitamins D and E are recommended. 
 
8.3 Paper III 
Hereditary lymphedema: characteristics and variations in 17 adult patients with 
Lymphedema Cholestasis Syndrome 1 (LCS1)/Aagenaes syndrome 
Introduction: In this study, lymphoedema in 17 out of 20 Norwegian adult patients 
with LCS1 was examined. Individual clinical variations in the group are described.  
Results: The lymphoedema in patients with LCS1 is similar to other hereditary 
lymphoedemas. However, fluid retention in the lower extremities is more pronounced, 
and lymphoedema is generally more extensive, as lymphoedema findings in the 
arms, face and trunk may be observed. Limited tissue fibrosis was observed, despite 
longstanding lymphoedema. 
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Conclusion: Approximately one-third of patients with LCS1 exhibit severe extremity 
lymphoedema (grades III and IV), and their condition requires close follow-up. More 
frequent use of compression in the upper extremities is advised.  
8.4 Paper IV 
A nine-year follow-up of diet and liver disease in patients with LCS1/Aagenaes 
syndrome 
Introduction: The aim of this follow-up study was to evaluate the progression of liver 
disease and nutritional status in patients with LCS1 over a period of nine years.  
Results: Dietary and biochemical data demonstrate few differences from 2000/2001 
until 2009/2010 compared to dietary recommendations and normal reference ranges 
for biochemical markers. Compared with the controls, the patients exhibited 
significantly higher levels of alkaline phosphatase (P=0.015 and P=0.002), Ȗ-
glutamyltransferase (P=0.001 and P<0.001), bile acids (P=0.037 and P=0.016), and 
fibrinogen (P= 0.046 and P<0.001) and lower albumin (P=0.033 and P<0.001) and Į-
tocopherol levels (P=0.011 and P=0.003) at baseline and follow-up, respectively. Our 
findings suggest the presence of low-grade hepatobiliary dysfunction in LCS1 
patients despite stable liver disease.  
Conclusion: The present study demonstrates that patients with LCS1 have a diet 
that is similar to that of healthy controls with no clinical worsening of liver disease 
over a nine-year period. 
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9 Discussion  
9.1 Methodological considerations 
9.1.1 Study design 
The study design included a combination of different methods or aspects of methods 
within the observational category (case-control, cross-sectional, cohort). Compared 
with randomised control trials, observational studies may not establish a cause-and-
effect relationship because the two groups may differ in ways other than the variable 
under study. This phenomenon is caused by larger confounding biases in 
observational studies; therefore, these studies often serve as descriptions of events 
rather than explanations for events [148] as can also be seen in this thesis.  
Other weaknesses include the limited power of the statistical calculations, which is a 
consequence of the small sample sizes. Control subjects were included in both 
studies as a reference group for nutritional and biochemical parameters. However, a 
limitation is that the control group was not similar in the two studies. A fundamental 
step in the design of clinical research is the computation of power and sample size 
[158]. Power calculations are performed to ensure that the sample size drawn from a 
population is sufficiently large to reflect the true value in the source population for a 
given probability, e.g., 95%. Due to the rarity of LCS1, power calculations were not 
performed. All patients with LCS1 in Norway were invited to participate in the first 
study. Various numbers of patients were evaluated as a group in the different papers; 
however, in each paper, at least 50% of currently living patients with LCS1 were 
included. An even higher proportion of subjects with LCS1 were included when only 
the age groups of interest are considered. This fact is believed to increase the 
strength of our conclusions despite the small sample size.  
The aims (presented in section 6) were primarily evaluated using a case-control 
study design. In addition, the study design can be viewed as cross-sectional given 
that data were obtained only once in both studies, as well as longitudinal (cohort) 
given that the two studies were performed nine years apart. Generally, case-control 
studies provide relatively weak empirical evidence, even when properly executed, 
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and case-control studies are less reliable than cohort studies [148]. We believe that 
combining the two case-control studies (performed nine years apart in a cohort 
fashion) strengthened the ability of the study to identify valid associations (paper IV). 
The inferences made are also strengthened by the fact that both case-control studies 
included a representative sample of Norwegian LCS1 patients.  
9.1.2 Validity 
Valid, precise and generalisable estimates of results can be obtained using the best 
suited study design as well as the best possible study conduct and data analysis 
[148]. If correctly used, these techniques would reduce bias or errors and lead to 
increased objectivity and accuracy in the estimates. The accuracy and precision of 
scientific work is typically challenged by limited resources (e.g., financial resources, 
staff, time, available study subjects) as was also observed in this project. Regardless, 
errors in estimation are traditionally classified as either systematic or random. 
Studies with few systematic errors are referred to as valid and exhibit a low grade of 
bias, whereas little random error will produce more precise estimates [148]. The 
validity of a study is often separated into internal validity and external 
validity/generalisability. Violations of internal validity can be classified into 
confounding, selection bias and information bias. Internal validity is considered a 
prerequisite for external validity [148].  
9.1.3 Internal validity 
Confounding 
Confounding is a considerable issue in observational studies, and the use of a case-
control design can give rise to several possible confounding variables. To reduce the 
confounding effects of gender and age, the subjects were matched according to 
these variables. In the first study, subjects were also matched by residential area, in 
particular to reduce the confounding effects of different local dietary habits and the 
availability of foods. Matching for residential area was not performed in the follow-up 
study due to a lack of financial resources and inconvenience, as all of the data were 
obtained in Oslo. The healthy controls in the follow-up study are likely not 
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representative of the general population, and these controls exhibited higher 
educational levels than the patients. Despite this fact, the results obtained from the 
control groups in the two studies were quite similar, strengthening their use as 
acceptable control groups to some extent.  
The patients in the follow-up study completed a weighed diet registration nine years 
ago. The patients may have had an increased understanding of and interest in the 
information derived from their dietary information than the controls and therefore may 
have completed the dietary records more thoroughly. Several patients reported low 
alcohol intake due to their knowledge of the adverse effects of alcohol consumption 
on the liver. This low intake may confound the liver biomarkers relative to healthy 
controls.  
Selection bias 
Selection biases result from the procedures used for selecting subjects to participate 
in the study as well as from factors that influence study participation. The biases 
occur due to differences between those who participate and those who decline to 
participate or are considered to be ineligible for the study. The observed associations 
will therefore be a mixture of forces that determine disease occurrence and other 
findings [148].  
Selection bias is of high concern in case-control studies and plays a major role in 
reducing validity. This project included a high percentage of Norwegian LCS1 
patients and is probably representative of the majority of the LCS1 patients in 
Norway. Regardless, both self-selection into the study and the exclusion of patients 
for the prognostic evaluation and follow-up are potential sources of selection bias. In 
this respect, O Aagenaes’s knowledge of the individual patients has been valuable 
for comparing non-participants against patients who were included in the studies. No 
patients appeared to be distinctly different from those included in the two studies with 
the exception of one patient with cirrhosis who was omitted in these evaluations 
[110]. Another weakness is that the project included a small sample size due to the 
rarity of the condition, making the estimates more vulnerable to extreme 
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observations. Patients who were not included could potentially skew the associations 
observed in the presented publications.  
The control group in the first study was randomly selected from the Norwegian 
population and matched to the patients with respect to age, sex, and residential area. 
The first of the five possible controls who consented to participate may have been 
more interested in health or differed in other ways from the general Norwegian 
population (with whom the patients were intended to be compared). After all, the 
matching of the control group of randomly selected persons from the general 
Norwegian population reduces bias. The control group in the follow-up study was 
more subject to selection bias, probably further weakening the results or 
comparisons between patients and controls in this study (compared with the first 
study). Furthermore, the inclusion of friends and colleagues may have influenced the 
usefulness of the follow-up study’s control group. Biases introduced with the control 
groups may have been particularly high in this project, and high levels of self-
selection bias, especially in the follow-up study, could threaten the validity of the 
conclusions. 
None of the patients or the controls were excluded in the data sampling process, but 
self-exclusion by patients who were not interested in participation or self-inclusion by 
control persons are forms of selection bias. Longitudinal studies are susceptible to 
bias by differential loss to follow-up and the lack of control over risk assignment, 
leading to confounder symmetry. Two of the patients were lost to follow-up in 
2009/2010.  
Information bias 
Inaccurate measurement of study variables or errors in the information obtained can 
occur to some extent in any study. In the papers presented here, the dietary 
evaluations are especially prone to information bias. In dietary surveys, under-
reporting is well known and includes both under-recording and under-eating [142]. 
The latter is due to less dietary intake than usual and could cause weight loss if it 
were persistent over a longer period. Under-recording leads to a discrepancy 
between energy intake and energy expenditure during the weight recording period.  
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The self-registration of weight and height by the participants in the first study could 
lead to differential misclassification of the BMR, the Goldberg cut-off or the BMI. In 
addition, individual weights were probably not correctly or equally adjusted for 
lymphoedema in either of the two studies and may have worsened the differential 
misclassification of these variables. This measurement error may also have arisen 
because some subjects underwent CDT close to the data sampling period, whereas 
others did not received such therapy. A better classification of these variables could 
have provided more representative energy intake data for the patient group than the 
data presented in the papers, possibly allowing the intake of vitamins and minerals in 
the patient group to reach recommendations (papers II and IV). The higher BMI 
observed in patients compared with controls was probably caused by excess weight 
related to lymphoedema.  
The nutrient intake evaluations for the patients group compared with healthy controls 
were based on the measured median intake from one single 4-day weighed record. A 
single 4-day registration cannot capture the habitual intake and may produce 
information bias. To determine the proportion of individuals at risk of inadequate 
intake of a particular nutrient, multiple records must be collected (e.g., 3 - 4 days four 
times a year) [159]. In particular, dietary evaluations require a longer collection period 
to draw valid conclusions. 
Because of the prospective design of the study, recall bias is less of a problem in this 
study. Other information biases may be due to differing equipment used for the 
biochemical analyses, especially in the comparisons from patient baseline to patient 
follow-up (paper IV).  
9.1.4 External validity/ generalisability
When selecting a subgroup from a target population, it is usually important to ensure 
that the subjects selected are as representative as possible to allow assumptions to 
be made regarding the source population and populations outside Norway. Due to 
the high percentage of LCS1 patients included, inferences of the results may be 
generalised beyond those subjects who were studied. The study results should only 
be generalised to populations that closely resemble those we studied and should 
most likely not be generalised to patients with non-specific forms of LCS. It is 
50 
 
unknown whether the factors that distinguish other groups from the studied group 
can modify the effect in question. Because of the heterogeneity of individuals with 
LCS1 as well as the possible heterogeneity of LCS1 patients outside Norway, one 
should be cautious in generalising the findings presented here. In the first study 
(paper I), it was important for the findings to be as generalisable as possible for 
patients in Norway; therefore, the patient with cirrhosis was omitted from the 
evalutions. 
 
9.2 Discussion of the main results 
A problem arises due to a lack of other comparable publications, as this is the first 
time the majority of LCS1 patients have been evaluated outside cholestatic periods. 
The similar biochemical and dietary findings in the two studies, which were 
performed nine years apart, strengthen the reliability of the conclusions.  
9.2.1 Diet 
The nutritional findings in the group of LCS1 patients who had recovered from the 
prolonged period of childhood cholestasis were similar to those of healthy control 
persons and general Norwegian nutritional recommendations (papers II and IV). The 
final height was normal, and the growth retardation that had been observed in 
previous years due to cholestasis was not present in our study subjects. Normal adult 
height in these patients has also been reported by Aagenaes [111]. 
To provide further details, the patients reported a lower dietary fat intake and 
exhibited lower serum Į-tocopherol levels than did healthy controls, both in 
2000/2001 and 2009/2010. The serum 25-OH D level was below normal reference 
ranges as also observed in the general population [160, 161]. The possible lower fat 
intake referred to in (papers II and IV) in this thesis may be due to habits and 
preferences that were acquired during cholestatic periods, especially at a young age. 
Patients may have experienced discomfort when eating greasy foods, possibly due to 
underlying cholestasis. The patients met most of the dietary recommendations for 
macronutrients, except for saturated fat, monounsaturated fat, refined sugar and 
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fibre. Supplements were needed to meet the micronutrient recommendations. Dietary 
intake of nutrients that is below the recommended levels has also been reported for 
the general Norwegian population [162]. 
However, the findings may be subject to measurement errors, e.g., under-reporting 
or under-eating as indicated by the low BMR:energy intake ratios. If the reported 
energy intake had been higher, recommendations could have been reached. 
Additionally, a tendency to ingest less fish and vegetables was observed in patients 
compared with the healthy controls and the general Norwegian population [162, 163]. 
In addition, the general Norwegian population exhibits fibre and fish consumption 
levels that are below recommendations [162]. These studies therefore suggest that 
patients with LCS1 may derive benefit from dietary counselling with respect to fat 
quality and carbohydrate (including fibre) intake, similar to the recommendations 
provided by health authorities for the general population.  
9.2.2 Liver disease 
Clinical signs of progression of liver disease were not observed during the nine-year 
follow-up period although some of the biochemical markers were significantly 
different than those of the healthy controls. Additionally, some of the biochemical 
markers in LCS1 patients were outside the normal reference ranges. The differences 
observed in biochemical markers between patients and controls may have been 
caused by a slow ongoing progression of liver disease. The significantly lower serum 
Į-tocopherol in LCS1 patients supports the possible presence of subclinical 
cholestasis [164, 165]. Both the lower fat intake and the recurrent cholestatic periods 
within the patient group are probably too few to have caused the lower Į-tocopherol 
levels observed, and our sample size was likely too small to detect such a 
relationship. The numbers of cholestatic periods are also subject to recall bias by the 
patients in addition to their difficulty in recalling subtle itching periods as cholestasis. 
This bias makes it difficult to draw any firm conclusions relating the presence of 
cholestatic periods and the lower plasma Į-tocopherol levels. Furthermore, 
hypoplasia of lymph vessels along the gut in LCS1 patients might exist and could 
potentially be a contributing factor to the lower Į-tocopherol levels observed [166]. 
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All patients included in these two studies who survived the first prolonged period of 
cholestasis, the biochemical findings in the baseline and follow-up studies were 
similar and reflect stable liver disease. The stability of the liver disease after puberty 
are also seen in the cirrhotic patient who was excluded from the group evaluation as 
well as in the two patients (aged 21 and 23 years) described in paper I in whom 
clinical-biochemistry indices had been persistently abnormal over the preceding few 
years, indicating the possible development of cirrhosis. Only minor changes in the 
biochemical markers were observed during the nine-year follow-up period in these 
three patients. The Ȗ-GT levels and ALP levels declined in all three patients during 
the nine-year follow-up period. The ALT levels increased slightly in two of the 
patients and are likely only a reflection of common variability. Additionally, the 
different analytic equipment used for biochemical marker testing may have caused 
some of the differences observed in the LCS1 patients between baseline and follow-
up. The findings of similar dietary intake and nutritional status in the LCS1 patients 
compared with healthy controls are reasonable when viewed in the light of the benign 
character of the liver disease observed in this patient group.  
The recommendations that adult patients with LCS1 should regularly monitor serum 
levels of vitamins D and E to ensure that levels of these vitamins are within reference 
ranges is based on findings from both 2000/2001 and 2009/2010. The Directorate of 
Health in Norway has recommended that the majority of the population should have 
25-OH D levels above 50 nmol/l to ensure adequate vitamin D status [167]. Given the 
lower Į-tocopherol levels in LCS1 patients as well as the age-related decline that 
was not observed in healthy controls (paper I), attention should also be paid to Į-
tocopherol levels [168, 169]. In addition, given the findings of possible low-grade 
chronic inflammation (papers I and IV), avoiding low Į-tocopherol values may be 
beneficial for LCS1 patients [170-172]. 
9.2.3 Lymphoedema 
An important aim of this work was also to describe lymphoedema in adult patients 
with LCS1 (paper III). Approximately one-third of the patients exhibited severe 
lymphoedema in the lower limbs (grades III and IV) that required close follow-up. The 
lymphoedema was similar to that observed in other hereditary lymphoedemas; 
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however, in LCS1, the lymphoedema was generally more extensive and often 
included lymphoedema in the arms, face and trunk. It is difficult to compare the 
lymphoedema grade in the LCS1 patients with other lymphoedematous diseases 
because of the worldwide lack of a uniform method of diagnosing lymphoedema 
[100]. The results are therefore heavily dependent upon the physicians who perform 
such evaluations and their experience with lymphoedema diseases. In this study, an 
experienced physician with knowledge of this field collaborated in acquiring these 
data, and the patient-related knowledge gained by O Aagenaes over several years 
also contributed to this evaluation. Limited tissue fibrosis was observed, despite 
longstanding lymphoedema, most likely due to patient awareness of the importance 
of lymphoedema treatment as well as close follow-up by physiotherapists trained in 
CDT. The importance of lymphoedema treatment and follow-up are well documented 
[173-175]. Some patients were advised to use compression garments on the upper 
extremities in addition to the compression applied to the lower extremities. Although 
LCS1 patients often exhibit extensive lymphoedema, good care may reduce some of 
the extra burden that it causes [176, 177]. A few patients also had albumin levels 
below normal reference ranges, but oedema formation resulting from these levels do 
not seem likely due to the fact that albumin concentrations typically must be below 20 
g/l before oedema forms. Moreover, the combination of liver disease and 
lymphoedema might make the LCS1 patients more vulnerable to adverse effects 
caused by low albumin levels.  
9.2.4 Prognosis 
More than 50% of the LCS1 patients can expect a fairly normal lifespan (paper I), 
and the evaluation of the same patients over a nine-year period suggests that 
currently, patients may exhibit an even better prognosis (paper IV). The average age 
of the Norwegian LCS1 patients in this study project at follow-up was 31 years. The 
oldest patient in the Norwegian LCS1 cohort is presently 70 years old. It is therefore 
difficult to project the true lifetime prognosis because too few patients have yet had 
the possibility reaching old age. All of the liver transplant patients have survived to 
date, but these patients are still very young, and it is still too early to provide any 
estimates of their prognosis.  
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Some prognostic calculations have been performed here to provide a comparison to 
other neonatal cholestatic disorders. If the LCS1 patients who died of haemorrhage 
are either omitted 1) (48 – 9 = 39, n = 39) or included, 2) (n = 48) in the prognostic 
evaluation (see below) due to the routine use of vitamin K in newborn patients, the 
estimates would be as follows:  
1) Nine children out of 39 patients have died of cirrhosis (3 patients) or been liver 
transplanted (6 patients) producing a probable shortened life expectancy of 9/39 = 
0.23 i.e., 23%). Additionally, it is likely that 2 adults died due to liver disease before 
reaching old (> 70 years) age (11/ 39 = 0.28 i.e. 28%). Summarised this yields a 
survival rate of about 72%. 
2) When the nine patients who died of haemorrhage before the 1940ies are included, 
and when three of these are expected to have died due to cirrhosis before old age 
(with a rate of cirrhosis before old age assumed to be 11/ 39 = 0.28; the estimate 
become 14/ 48 = 0.29 i.e. 29%).  
The estimates given in 1) and 2) provide a lifetime prognosis of approximately 70% 
given that their liver diseases are stable and no one dies before the age of 70. At 
present, we do not know whether patients without proven cirrhosis (who were 
included in this study) have a longer life expectancy than was estimated for the entire 
group (paper I). However, this estimate seems probable; hence, the conclusion 
provided in paper IV.  
The overall prognosis of LCS1 is highly variable and is largely dependent on the 
progression of cholestasis as also observed in other genetic syndromes associated 
with severe neonatal cholestasis. In Į-1-antitrypsin deficiency, a relatively good 
prognosis has been reported, and only approximately 8 - 11% of patients will develop 
clinically significant liver disease during their lifetime [178]. These data suggest that 
Į-1-antitrypsin deficiency patients have a better outcome than LCS1 patients.  
In Alagille syndrome, the prognosis varies among the various published reports, but 
overall survival has been reported to average 70%; up to 50% of patients require liver 
transplantation [179, 180]. Other clinical features in addition to liver disease 
complicate the prognosis of these patients [180], and comparisons with LCS1 should 
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be made with caution. Emerick et al reported a 20-year predicted life expectancy of 
75% for all patients, 80% for those not requiring liver transplantation, and 60% for 
those who required liver transplantation [181]. In Alagille syndrome 33% of patients 
with neonatal cholestasis are reported to require liver transplant [179]. In LCS1, three 
out of 36 patients died of cirrhosis before liver transplantation was available, and 
additionally 6 out of then 39 has been transplanted indicating that approximately 8% - 
23% of patients need liver transplantation. This rate is lower than the rates that have 
been reported for Alagille syndrome. Moreover, infants with Alagille syndrome who 
present with cholestasis have a 50% probability of long-term survival without liver 
transplantation [182]. In LCS1, all patients present with neonatal cholestasis, but 
most seem to have long-term survival without liver transplantation (30/ 39 = 77%). 
Three patients were diagnosed with LCS1 after undergoing transplantation. Given 
these data, LCS1 patients seem to have a better prognosis than patients with Alagille 
syndrome.  
Patients with NAICC and most PFIC patients, including Greenland familial 
cholestasis, are candidates for liver transplantation, and have poorer outcomes than 
patients with the other types of neonatal cholestasis mentioned above. Some of 
these patients develop rapid liver failure in the first six months of life, some develop 
severe cirrhosis in childhood with death before 10 years of age, and a few develop 
slowly progressive cirrhosis with death in adulthood [27, 183-186].  
Concluding remarks 
The reliability of our dietary and biochemical findings is strengthened by the 
similarities observed at the baseline and during follow-up. Our findings are also 
strengthened when compared to the findings by Aagenaes et al. in 1968 and 1998 
(paper IV).  
The validity of the major dietary findings (fat and fibre) as well as the findings of the 
subclinical, slowly progressive liver disease (based on our evaluations of biochemical 
liver markers) appears to be acceptable. The external validity of these findings 
outside the Norwegian cohort or in spontaneous cases may be problematic due to 
modifier genes and environmental influences [187] but may be considered good for 
Norwegian patients without proven cirrhosis.  
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The theoretical implications of the results of this thesis include the following: 
increasing awareness of the possibility of subclinical cholestasis in these patients, 
increasing patient awareness of diet; ensuring careful lymphoedema care and 
ensuring serum vitamin D and E monitoring. An information sheet provided by SSD 
about LCS1 could include these findings.  
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10 Conclusions 
This work indicates that greater than 50% of LCS1 patients without proven cirrhosis 
probably can expect a normal life span (paper I), and the prognosis may be even 
better in patients who survive the first prolonged period of cholestasis in childhood 
(paper IV). The liver disease appears to be clinically stable despite significant 
different biochemical liver markers compared to healthy controls both in baseline and 
follow-up. The dietary intake and nutritional status in this patient group is similar to 
healthy controls and the general Norwegian population (papers II and IV). 
Furthermore, in the LCS1 patient group, only minor deviations from the Norwegian 
dietary recommendations are observed (papers II and IV).  The lymphoedema that 
develops in one-third of LCS1 patients is serious and requires close follow-up, but 
the lymphoedema is generally well managed with compression and CDT (paper III).   
Overall, the care and follow-up of the LCS1 patients in this group seems satisfactory, 
but patients may benefit from following the Norwegian dietary guidelines, with a 
specific emphasis on carbohydrate and fat quality, in addition to regular monitoring of 
serum vitamin D and E levels.  
The findings presented in the thesis may be applicable to adult LCS1 patients 
worldwide.  
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11 Future perspectives 
Continuing efforts are needed to reveal the exact genetic location of the LCS1 
mutation and the underlying reason for the cholestasis that is observed in LCS1. 
Whether the cholestasis and lymphoedema are caused by the same aetiology is 
beyond the scope of this thesis and requires further exploration. Identifying the 
location of the gene could also be important to establish the carrier frequency in the 
population of the most affected areas in southwestern Norway.  
Other future goals may also include investigating the possibility of providing more 
specific dietary interventions as well as performing other therapeutic interventions to 
reduce the number of erysipelas episodes or the fibrosis observed in lymphoedema.  
59 
 
References 
1. En sjelden guide. For deg som har eller møter mennesker med sjeldne tilstander.  
IS-1021 edn: Helsedirektoratet; 2012 Januar. 
KWWSZZZVMHOGQHGLDJQRVHUQR"N VMHOGQHGLDJQRVHU6DPRUJDQLVHULQJDYVMHOGHQIHOWHW	DLG  
2. Heiberg A, Frich J, Rottingen JA: [In Process Citation]. Tidsskrift for den Norske 
laegeforening : tidsskrift for praktisk medicin, ny raekke 2014, 134(8):809-810. 
3. En sjelden historie. In., IS-1185. ISBN-nr. 82-8081-044-7 edn: Sosial- og 
helsedirektoratet; 07/2004. 
4. Council Recommendation on an action in the field of rare diseases [http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:EN:PDF] 
5. Rare Disease Information [https://www.rarediseases.org/rare-disease-information] 
6. Ferlini A, Scotton C, Novelli G: Biomarkers in rare diseases. Public health 
genomics 2013, 16(6):313-321. 
7. Rare Disorders 
http://www.sjeldnediagnoser.no/docs/PDF/Annet/09_SSDfolder_engelsk_4s.pdf  
8. Godkjenning av nasjonale tjenester i spesialisthelsetjenesten (Norwegian). 
Veileder til Forskrift nr 1706 av 17 desember 2010. Revidert 30.7.2013. 
9. Aagenaes O, van der Hagen CB, Refsum S: Hereditary recurrent intrahepatic 
cholestasis from birth. Archives of disease in childhood 1968, 43(232):646-657. 
10. Aagenaes O: Hereditary recurrent cholestasis with lymphoedema--two new 
families. Acta paediatrica Scandinavica 1974, 63(3):465-471. 
11. Wain HM, Bruford EA, Lovering RC, Lush MJ, Wright MW, Povey S: Guidelines 
for human gene nomenclature. Genomics 2002, 79(4):464-470. 
12. Aagenaes syndrome [http://omim.org/entry/214900] 
13. Schuppan D, Afdhal NH: Liver cirrhosis. Lancet 2008, 371(9615):838-851. 
14. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F: The 
burden of liver disease in Europe: a review of available epidemiological data. 
Journal of hepatology 2013, 58(3):593-608. 
15. Zatonski WA, Sulkowska U, Manczuk M, Rehm J, Boffetta P, Lowenfels AB, La 
Vecchia C: Liver cirrhosis mortality in Europe, with special attention to Central 
and Eastern Europe. European addiction research 2010, 16(4):193-201. 
16. Khashab M, Tector AJ, Kwo PY: Epidemiology of acute liver failure. Current 
gastroenterology reports 2007, 9(1):66-73. 
17. Streetz KL, Tacke F, Koch A, Trautwein C: [Acute liver failure. Diagnosis and 
therapy]. Medizinische Klinik, Intensivmedizin und Notfallmedizin 2013, 108(8):639-
645. 
18. Bell BP, Manos MM, Zaman A, Terrault N, Thomas A, Navarro VJ, Dhotre KB, 
Murphy RC, Van Ness GR, Stabach N et al: The epidemiology of newly diagnosed 
chronic liver disease in gastroenterology practices in the United States: results 
from population-based surveillance. The American journal of gastroenterology 
2008, 103(11):2727-2736; quiz 2737. 
19. van Mil SW, Houwen RH, Klomp LW: Genetics of familial intrahepatic cholestasis 
syndromes. Journal of medical genetics 2005, 42(6):449-463. 
20. Jungst C, Lammert F: Cholestatic liver disease. Digestive diseases 2013, 31(1):152-
154. 
21. Gossard AA, Talwalkar JA: Cholestatic liver disease. The Medical clinics of North 
America 2014, 98(1):73-85. 
60 
22. European Association for the Study of the Liver: EASL Clinical Practice
Guidelines: management of cholestatic liver diseases. Journal of hepatology 2009,
51(2):237-267.
23. Ling SC: Congenital cholestatic syndromes: what happens when children grow
up? Canadian journal of gastroenterology = Journal canadien de gastroenterologie
2007, 21(11):743-751.
24. Santos JL, Choquette M, Bezerra JA: Cholestatic liver disease in children. Current
gastroenterology reports 2010, 12(1):30-39.
25. Hartley JL, Davenport M, Kelly DA: Biliary atresia. Lancet 2009, 374(9702):1704-
1713. 
26. Leonard LD, Chao G, Baker A, Loomes K, Spinner NB: Clinical utility gene card
for: Alagille Syndrome (ALGS). European journal of human genetics : EJHG 2014, 
22(3). 
27. Jacquemin E: Progressive familial intrahepatic cholestasis. Clinics and research in
hepatology and gastroenterology 2012, 36 Suppl 1:S26-35. 
28. Boonstra K, Beuers U, Ponsioen CY: Epidemiology of primary sclerosing
cholangitis and primary biliary cirrhosis: a systematic review. Journal of 
hepatology 2012, 56(5):1181-1188. 
29. Lazaridis KN, Talwalkar JA: Clinical epidemiology of primary biliary cirrhosis:
incidence, prevalence, and impact of therapy. Journal of clinical gastroenterology 
2007, 41(5):494-500. 
30. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H: Incidence and
prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and 
autoimmune hepatitis in a Norwegian population. Scandinavian journal of 
gastroenterology 1998, 33(1):99-103. 
31. Hofmann AF: The continuing importance of bile acids in liver and intestinal
disease. Archives of internal medicine 1999, 159(22):2647-2658. 
32. Schiff ER, Sorrell MF, Maddrey WC: Schiff's Diseases of the Liver, vol. 1:
Lippincott Williams & Wilkins; 2007. 
33. Hirschfield GM, Chapman RW, Karlsen TH, Lammert F, Lazaridis KN, Mason AL:
The genetics of complex cholestatic disorders. Gastroenterology 2013, 144(7):1357-
1374. 
34. Reshetnyak VI: Physiological and molecular biochemical mechanisms of bile
formation. World journal of gastroenterology : WJG 2013, 19(42):7341-7360. 
35. Jansen PL, Muller M, Sturm E: Genes and cholestasis. Hepatology 2001, 34(6):1067-
1074. 
36. Balistreri WF, Bezerra JA, Jansen P, Karpen SJ, Shneider BL, Suchy FJ: Intrahepatic
cholestasis: summary of an American Association for the Study of Liver Diseases 
single-topic conference. Hepatology 2005, 42(1):222-235. 
37. Colombo C, Okolicsanyi L, Strazzabosco M: Advances in familial and congenital
cholestatic diseases. Clinical and diagnostic implications. Digestive and liver 
disease : official journal of the Italian Society of Gastroenterology and the Italian 
Association for the Study of the Liver 2000, 32(2):152-159. 
38. Hartley JL, Gissen P, Kelly DA: Alagille syndrome and other hereditary causes of
cholestasis. Clinics in liver disease 2013, 17(2):279-300. 
39. Nakamura K, Tanoue A: Etiology of biliary atresia as a developmental anomaly:
recent advances. Journal of hepato-biliary-pancreatic sciences 2013, 20(5):459-464. 
40. Turnpenny PD, Ellard S: Alagille syndrome: pathogenesis, diagnosis and
management. European journal of human genetics : EJHG 2012, 20(3):251-257. 
61 
 
41. Kim BJ, Fulton AB: The genetics and ocular findings of Alagille syndrome. 
Seminars in ophthalmology 2007, 22(4):205-210. 
42. Gissen P, Johnson CA, Morgan NV, Stapelbroek JM, Forshew T, Cooper WN, 
McKiernan PJ, Klomp LW, Morris AA, Wraith JE et al: Mutations in VPS33B, 
encoding a regulator of SNARE-dependent membrane fusion, cause 
arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome. Nature genetics 
2004, 36(4):400-404. 
43. Wilkins BJ, Lorent K, Matthews RP, Pack M: p53-mediated biliary defects caused 
by knockdown of cirh1a, the zebrafish homolog of the gene responsible for North 
American Indian Childhood Cirrhosis. PloS one 2013, 8(10):e77670. 
44. Turan S, Topcu B, Gokce I, Guran T, Atay Z, Omar A, Akcay T, Bereket A: Serum 
alkaline phosphatase levels in healthy children and evaluation of alkaline 
phosphatase z-scores in different types of rickets. Journal of clinical research in 
pediatric endocrinology 2011, 3(1):7-11. 
45. Wildhaber BE: Biliary atresia: 50 years after the first kasai. ISRN surgery 2012, 
2012:132089. 
46. Paumgartner G, Pusl T: Medical treatment of cholestatic liver disease. Clinics in 
liver disease 2008, 12(1):53-80, viii. 
47. Bolier R, Oude Elferink RP, Beuers U: Advances in pathogenesis and treatment of 
pruritus. Clinics in liver disease 2013, 17(2):319-329. 
48. Heathcote J: The pruritus of cholestasis is relieved by an opiate antagonist: is this 
pruritus a centrally mediated phenomenon? Hepatology 1996, 23(5):1280-1282. 
49. Hofmann AF, Hagey LR: Bile acids: chemistry, pathochemistry, biology, 
pathobiology, and therapeutics. Cellular and molecular life sciences : CMLS 2008, 
65(16):2461-2483. 
50. Carrion AF, Bhamidimarri KR: Liver transplant for cholestatic liver diseases. 
Clinics in liver disease 2013, 17(2):345-359. 
51. Young S, Kwarta E, Azzam R, Sentongo T: Nutrition assessment and support in 
children with end-stage liver disease. Nutrition in clinical practice : official 
publication of the American Society for Parenteral and Enteral Nutrition 2013, 
28(3):317-329. 
52. Purnak T, Yilmaz Y: Liver disease and malnutrition. Best practice & research 
Clinical gastroenterology 2013, 27(4):619-629. 
53. Johnson TM, Overgard EB, Cohen AE, DiBaise JK: Nutrition assessment and 
management in advanced liver disease. Nutrition in clinical practice : official 
publication of the American Society for Parenteral and Enteral Nutrition 2013, 
28(1):15-29. 
54. Smart KM, Alex G, Hardikar W: Feeding the child with liver disease: a review and 
practical clinical guide. Journal of gastroenterology and hepatology 2011, 
26(5):810-815. 
55. Sokol RJ: Fat-soluble vitamins and their importance in patients with cholestatic 
liver diseases. Gastroenterology clinics of North America 1994, 23(4):673-705. 
56. Choi I, Lee S, Hong YK: The new era of the lymphatic system: no longer 
secondary to the blood vascular system. Cold Spring Harbor perspectives in 
medicine 2012, 2(4):a006445. 
57. Mortimer PS, Rockson SG: New developments in clinical aspects of lymphatic 
disease. The Journal of clinical investigation 2014, 124(3):915-921. 
58. Szuba A, Rockson SG: Lymphedema: anatomy, physiology and pathogenesis. 
Vascular medicine 1997, 2(4):321-326. 
62 
 
59. Rockson SG: Lymphedema. The American journal of medicine 2001, 110(4):288-
295. 
60. Powell AA, Armstrong MA: Peripheral edema. American family physician 1997, 
55(5):1721-1726. 
61. Wiig H, Swartz MA: Interstitial fluid and lymph formation and transport: 
physiological regulation and roles in inflammation and cancer. Physiological 
reviews 2012, 92(3):1005-1060. 
62. Titze J: Interstitial fluid homeostasis and pressure: news from the black box. 
Kidney international 2013, 84(5):869-871. 
63. Oliver G, Detmar M: The rediscovery of the lymphatic system: old and new 
insights into the development and biological function of the lymphatic 
vasculature. Genes & development 2002, 16(7):773-783. 
64. Williams AF, Franks PJ, Moffatt CJ: Lymphoedema: estimating the size of the 
problem. Palliative medicine 2005, 19(4):300-313. 
65. Vaillant L GN: [Infectious complications of lymphedema]. Rev Med Interne 2002, 
Jun;23 (Suppl 3):403s-407s. 
66. Inghammar M, Rasmussen M, Linder A: Recurrent erysipelas - risk factors and 
clinical presentation. BMC infectious diseases 2014, 14(1):270. 
67. Damstra RJ, van Steensel MA, Boomsma JH, Nelemans P, Veraart JC: Erysipelas as 
a sign of subclinical primary lymphoedema: a prospective quantitative 
scintigraphic study of 40 patients with unilateral erysipelas of the leg. The British 
journal of dermatology 2008, 158(6):1210-1215. 
68. Blome C, Sandner A, Herberger K, Augustin M: Lymphedema - the long way to 
diagnosis and therapy. VASA Zeitschrift fur Gefasskrankheiten 2013, 42(5):363-369. 
69. Connor MP, Gamelli R: Challenges of cellulitis in a lymphedematous extremity: a 
case report. Cases journal 2009, 2:9377. 
70. Kasai-Sakamoto A, Yokoyama Y, Mizunuma H: A case of cellulitis that 
complicated lymphedema of the lower limb and produced systemic inflammatory 
response syndrome (SIRS). European journal of gynaecological oncology 2006, 
27(4):419-421. 
71. Rockson SG: The unique biology of lymphatic edema. Lymphatic research and 
biology 2009, 7(2):97-100. 
72. Saito Y, Nakagami H, Kaneda Y, Morishita R: Lymphedema and therapeutic 
lymphangiogenesis. BioMed research international 2013, 2013:804675. 
73. Bellini C, Hennekam RC: Clinical disorders of primary malfunctioning of the 
lymphatic system. Advances in anatomy, embryology, and cell biology 2014, 
214:187-204. 
74. Casley-Smith JR: Alterations of untreated lymphedema and it's grades over time. 
Lymphology 1995, 28(4):174-185. 
75. Szuba A, Rockson SG: Lymphedema: classification, diagnosis and therapy. 
Vascular medicine 1998, 3(2):145-156. 
76. Lymphatic filariasis [http://www.who.int/mediacentre/factsheets/fs102/en/] 
77. Rockson SG, Rivera KK: Estimating the population burden of lymphedema. 
Annals of the New York Academy of Sciences 2008, 1131:147-154. 
78. Moffatt CJ, Franks PJ, Doherty DC, Williams AF, Badger C, Jeffs E, Bosanquet N, 
Mortimer PS: Lymphoedema: an underestimated health problem. QJM : monthly 
journal of the Association of Physicians 2003, 96(10):731-738. 
79. Petlund C: Behandling av lymfødem. Tidsskrift for Nosk lægeforening 1987(6). 
63 
 
80. Murdaca G, Cagnati P, Gulli R, Spano F, Puppo F, Campisi C, Boccardo F: Current 
views on diagnostic approach and treatment of lymphedema. The American 
journal of medicine 2012, 125(2):134-140. 
81. Connell F, Brice G, Mortimer P: Phenotypic characterization of primary 
lymphedema. Annals of the New York Academy of Sciences 2008, 1131:140-146. 
82. Schulte-Merker S, Sabine A, Petrova TV: Lymphatic vascular morphogenesis in 
development, physiology, and disease. The Journal of cell biology 2011, 193(4):607-
618. 
83. Gordon K, Schulte D, Brice G, Simpson MA, Roukens MG, van Impel A, Connell F, 
Kalidas K, Jeffery S, Mortimer PS et al: Mutation in vascular endothelial growth 
factor-C, a ligand for vascular endothelial growth factor receptor-3, is associated 
with autosomal dominant milroy-like primary lymphedema. Circulation research 
2013, 112(6):956-960. 
84. Smeltzer DM, Stickler GB, Schirger A: Primary lymphedema in children and 
adolescents: a follow-up study and review. Pediatrics 1985, 76(2):206-218. 
85. Ferrell RE, Finegold DN: Research perspectives in inherited lymphatic disease: an 
update. Annals of the New York Academy of Sciences 2008, 1131:134-139. 
86. Mendola A, Schlogel MJ, Ghalamkarpour A, Irrthum A, Nguyen HL, Fastre E, 
Bygum A, van der Vleuten C, Fagerberg C, Baselga E et al: Mutations in the 
VEGFR3 signaling pathway explain 36% of familial lymphedema. Molecular 
syndromology 2013, 4(6):257-266. 
87. Levinson KL, Feingold E, Ferrell RE, Glover TW, Traboulsi EI, Finegold DN: Age of 
onset in hereditary lymphedema. The Journal of pediatrics 2003, 142(6):704-708. 
88. Michelini S, Degiorgio D, Cestari M, Corda D, Ricci M, Cardone M, Mander A, 
Famoso L, Contini E, Serrani R et al: Clinical and genetic study of 46 Italian 
patients with primary lymphedema. Lymphology 2012, 45(1):3-12. 
89. Wu X, Liu NF: FOXC2 transcription factor: a novel regulator of 
lymphangiogenesis. Lymphology 2011, 44(1):35-41. 
90. Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL, McTigue MA, 
Alitalo K, Finegold DN: Missense mutations interfere with VEGFR-3 signalling in 
primary lymphoedema. Nature genetics 2000, 25(2):153-159. 
91. Bos FL, Caunt M, Peterson-Maduro J, Planas-Paz L, Kowalski J, Karpanen T, van 
Impel A, Tong R, Ernst JA, Korving J et al: CCBE1 is essential for mammalian 
lymphatic vascular development and enhances the lymphangiogenic effect of 
vascular endothelial growth factor-C in vivo. Circulation research 2011, 
109(5):486-491. 
92. Alitalo K: The lymphatic vasculature in disease. Nature medicine 2011, 
17(11):1371-1380. 
93. Gordon K, Spiden SL, Connell FC, Brice G, Cottrell S, Short J, Taylor R, Jeffery S, 
Mortimer PS, Mansour S et al: FLT4/VEGFR3 and Milroy disease: novel 
mutations, a review of published variants and database update. Human mutation 
2013, 34(1):23-31. 
94. Jeltsch M, Jha SK, Tvorogov D, Anisimov A, Leppanen VM, Holopainen T, Kivela R, 
Ortega S, Karpanen T, Alitalo K: CCBE1 Enhances Lymphangiogenesis via 
ADAMTS3-Mediated VEGF-C Activation. Circulation 2014. 
95. Hennekam RC, Geerdink RA, Hamel BC, Hennekam FA, Kraus P, Rammeloo JA, 
Tillemans AA: Autosomal recessive intestinal lymphangiectasia and lymphedema, 
with facial anomalies and mental retardation. American journal of medical genetics 
1989, 34(4):593-600. 
64 
96. Kinmonth JB: Management of some abnormalities of the chylous return.
Proceedings of the Royal Society of Medicine 1972, 65(8):721-722.
97. Lazareth I: [Classification of lymphedema]. Rev Med Interne 2002, 23(Suppl
3):375s-378s.
98. Kerchner K, Fleischer A, Yosipovitch G: Lower extremity lymphedema update:
pathophysiology, diagnosis, and treatment guidelines. Journal of the American
Academy of Dermatology 2008, 59(2):324-331.
99. Greene A: Primary Lymphedema: Definition of Onset Based on Developmental
Age. Plastic and Reconstructive Surgery 2012, 129(1):221e.
100. International Society of L: The diagnosis and treatment of peripheral 
lymphedema: 2013 Consensus Document of the International Society of
Lymphology. Lymphology 2013, 46(1):1-11.
101. Miller AJ, Bruna J, Beninson J: A universally applicable clinical classification of 
lymphedema. Angiology 1999, 50(3):189-192.
102. Lee BB, Andrade M, Antignani PL, Boccardo F, Bunke N, Campisi C, Damstra R, 
Flour M, Forner-Cordero I, Gloviczki P et al: Diagnosis and treatment of primary
lymphedema. Consensus document of the International Union of Phlebology
(IUP)-2013. International angiology : a journal of the International Union of
Angiology 2013, 32(6):541-574.
103. Tiwari A, Cheng KS, Button M, Myint F, Hamilton G: Differential diagnosis, 
investigation, and current treatment of lower limb lymphedema. Archives of
surgery 2003, 138(2):152-161.
104. Dalal A, Eskin-Shwartz M, Mimouni D, Ray S, Days W, Hodak E, Leibovici L, Paul 
M: Interventions for the prevention of recurrent erysipelas and cellulitis. In:
Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd; 2012.
105. Morgan PA, Murray S, Moffatt CJ, Honnor A: The challenges of managing complex 
lymphoedema/chronic oedema in the UK and Canada. International wound journal
2012, 9(1):54-69.
106. Lasinski BB, McKillip Thrift K, Squire D, Austin MK, Smith KM, Wanchai A, Green 
JM, Stewart BR, Cormier JN, Armer JM: A systematic review of the evidence for
complete decongestive therapy in the treatment of lymphedema from 2004 to
2011. PM & R : the journal of injury, function, and rehabilitation 2012, 4(8):580-601.
107. Lasinski BB: Complete decongestive therapy for treatment of lymphedema. 
Seminars in oncology nursing 2013, 29(1):20-27.
108. Zaleska M, Olszewski WL, Durlik M: The effectiveness of intermittent pneumatic 
compression in long-term therapy of lymphedema of lower limbs. Lymphatic
research and biology 2014, 12(2):103-109.
109. Mehrara BJ, Zampell JC, Suami H, Chang DW: Surgical management of 
lymphedema: past, present, and future. Lymphatic research and biology 2011,
9(3):159-167.
110. Aagenaes O: Personal communication. In.; 2014: Number of diagnosed cases with 
LCS1 in other countires than Norway.
111. Aagenaes O: Hereditary cholestasis with lymphoedema (Aagenaes syndrome, 
cholestasis-lymphoedema syndrome). New cases and follow-up from infancy to
adult age. Scandinavian journal of gastroenterology 1998, 33(4):335-345.
112. Bull LN, Roche E, Song EJ, Pedersen J, Knisely AS, van Der Hagen CB, Eiklid K, 
Aagenaes O, Freimer NB: Mapping of the locus for cholestasis-lymphedema
syndrome (Aagenaes syndrome) to a 6.6-cM interval on chromosome 15q.
American journal of human genetics 2000, 67(4):994-999.
65 
 
113. Aagenaes O, Sigstad H, Bjorn-Hansen R: Lymphoedema in hereditary recurrent 
cholestasis from birth. Archives of disease in childhood 1970, 45(243):690-695. 
114. Sigstad H, Aagenaes O, Bjorn-Hansen RW, Rootwelt K: Primary lymphoedema 
combined with hereditary recurrent intrahepatic cholestasis. Acta medica 
Scandinavica 1970, 188(3):213-219. 
115. Aagenaes O MS: Hereditary intrahepatic cholestasis with lymphedema--Aagenaes 
syndrome. TidsskrNor Laegeforen 1993, 113: 3673-3677. 
116. Aagenaes Ø HT: Hereditary neonatal cholestasis in Norway. . In: Cholestasis in 
infancy. Edited by Kasai M SK: University of Tokyo Press; 1980: 141-151. 
117. Sharp HL, Krivit W: Hereditary lymphedema and obstructive jaundice. The 
Journal of pediatrics 1971, 78(3):491-496. 
118. Fruhwirth M, Janecke AR, Muller T, Carlton VE, Kronenberg F, Offner F, Knisely 
AS, Geleff S, Song EJ, Simma B et al: Evidence for genetic heterogeneity in 
lymphedema-cholestasis syndrome. The Journal of pediatrics 2003, 142(4):441-447. 
119. Vajro P, Romano A, Fontanello A, Oggero V, Vecchione R, Shmerling DH: 
Aagenaes's syndrome in an Italian child. Acta paediatrica Scandinavica 1984, 
73(5):695-696. 
120. Pawlowska J SJ, Wroblewska M, Wozniewicz B: Aagenaes Syndrome Mimicking 
Extrahepatic Biliary Atresia. Surg Childh Intern 1995, 111(1):54-60. 
121. Morris AA, Sequeira JS, Malone M, Slaney SF, Clayton PT: Parent-child 
transmission of infantile cholestasis with lymphoedema (Aagenaes syndrome). 
Journal of medical genetics 1997, 34(10):852-853. 
122. Dang S, Sigal Y, Davies D: Recurrent cellulitis in a case of Aagenaes syndrome. 
Clinical pediatrics 2009, 48(8):873-874. 
123. Danks DM, Campbell PE, Jack I, Rogers J, Smith AL: Studies of the aetiology of 
neonatal hepatitis and biliary atresia. Archives of disease in childhood 1977, 
52(5):360-367. 
124. Jensen K, Marzioni M, Munshi K, Afroze S, Alpini G, Glaser S: Autocrine 
regulation of biliary pathology by activated cholangiocytes. American journal of 
physiology Gastrointestinal and liver physiology 2012, 302(5):G473-483. 
125. Chen J, Zhao KN, Liu GB: Estrogen-induced cholestasis: pathogenesis and 
therapeuticimplications. Hepato-gastroenterology 2013, 60(126):1289-1296. 
126. Bull LN: Hereditary forms of intrahepatic cholestasis. Current opinion in genetics 
& development 2002, 12(3):336-342. 
127. Shah S, Conlin LK, Gomez L, Aagenaes O, Eiklid K, Knisely AS, Mennuti MT, 
Matthews RP, Spinner NB, Bull LN: CCBE1 mutation in two siblings, one 
manifesting lymphedema-cholestasis syndrome, and the other, fetal hydrops. 
PloS one 2013, 8(9):e75770. 
128. Stankiewicz P, Lupski JR: Structural variation in the human genome and its role 
in disease. Annual review of medicine 2010, 61:437-455. 
129. Evans AL, Brice G, Sotirova V, Mortimer P, Beninson J, Burnand K, Rosbotham J, 
Child A, Sarfarazi M: Mapping of primary congenital lymphedema to the 5q35.3 
region. American journal of human genetics 1999, 64(2):547-555. 
130. Generell veileder i pediatri. General guidelines in paediatry. 
[http://www.helsebiblioteket.no/retningslinjer/pediatri/mage-tarm-lever-
ern%C3%A6ring/gult-spedbarn-eldre] 
131. Bidlack WR: Interrelationships of food, nutrition, diet and health: the National 
Association of State Universities and Land Grant Colleges White Paper. Journal 
of the American College of Nutrition 1996, 15(5):422-433. 
66 
 
132. Willett WC, Stampfer MJ: Current evidence on healthy eating. Annual review of 
public health 2013, 34:77-95. 
133. Neeha VS, Kinth P: Nutrigenomics research: a review. Journal of food science and 
technology 2013, 50(3):415-428. 
134. Diet, nutrition and the prevention of chronic diseases. In: World Health 
Organization technical report series. vol. 916; 2003: i-viii, 1-149, backcover. 
135. Nordic Nutrition Recommendations 2012 Integrating nutrition and physical 
activity, vol. 2014:002, 5th edition edn. [København]: Nordisk Ministeråd; 2014. 
136. Helsedirektoratet: Anbefalinger om kosthold,ernæring og fysisk aktivitet. In.; 
2012. 
137. Livingstone MB: Assessment of food intakes: are we measuring what people eat? 
British journal of biomedical science 1995, 52(1):58-67. 
138. Tabacchi G, Amodio E, Di Pasquale M, Bianco A, Jemni M, Mammina C: Validation 
and reproducibility of dietary assessment methods in adolescents: a systematic 
literature review. Public health nutrition 2013:1-15. 
139. Ortiz-Andrellucchi A, Henriquez-Sanchez P, Sanchez-Villegas A, Pena-Quintana L, 
Mendez M, Serra-Majem L: Dietary assessment methods for micronutrient intake 
in infants, children and adolescents: a systematic review. The British journal of 
nutrition 2009, 102 Suppl 1:S87-117. 
140. Roman-Vinas B, Serra-Majem L, Ribas-Barba L, Ngo J, Garcia-Alvarez A, 
Wijnhoven TM, Tabacchi G, Branca F, de Vries J, de Groot LC: Overview of 
methods used to evaluate the adequacy of nutrient intakes for individuals and 
populations. The British journal of nutrition 2009, 101 Suppl 2:S6-11. 
141. Kath Roberts SJF: Review of dietary assessment methods in public health. In. 
Edited by Di Swanston NOO; 2010. 
142. Bingham SA: Limitations of the various methods for collecting dietary intake 
data. Annals of nutrition & metabolism 1991, 35(3):117-127. 
143. Henriquez-Sanchez P, Sanchez-Villegas A, Doreste-Alonso J, Ortiz-Andrellucchi A, 
Pfrimer K, Serra-Majem L: Dietary assessment methods for micronutrient intake: 
a systematic review on vitamins. The British journal of nutrition 2009, 102 Suppl 
1:S10-37. 
144. Trabulsi J, Schoeller DA: Evaluation of dietary assessment instruments against 
doubly labeled water, a biomarker of habitual energy intake. American journal of 
physiology Endocrinology and metabolism 2001, 281(5):E891-899. 
145. Hill RJ, Davies PS: The validity of self-reported energy intake as determined 
using the doubly labelled water technique. The British journal of nutrition 2001, 
85(4):415-430. 
146. A short review of dietary assessment methods used in National and Scottish 
Research Studies. 
[http://multimedia.food.gov.uk/multimedia/pdfs/scotdietassessmethods.pdf] 
147. Livingstone MB, Black AE: Markers of the validity of reported energy intake. The 
Journal of nutrition 2003, 133 Suppl 3:895S-920S. 
148. Rothman KJ, Greenland S, Lash TL: Modern epidemiology. Philadelphia: Lippincott 
Williams & Wilkins; 2008. 
149. Rimestad AH LE, Nordbotten A (2000). . The Norwegian food composition table 
and the database for nutrient calculations at the Institute for Nutrition Research. 
Norwegian Journal of Epidemiology 2000, 10: 7-16. 
150. Energy and protein requirements. Report of a joint FAO/WHO/UNU Expert 
Consultation. In: World Health Organization technical report series. vol. 724; 1985: 
1-206. 
67 
 
151. Goldberg GR, Black AE, Jebb SA, Cole TJ, Murgatroyd PR, Coward WA, Prentice 
AM: Critical evaluation of energy intake data using fundamental principles of 
energy physiology: 1. Derivation of cut-off limits to identify under-recording. 
European journal of clinical nutrition 1991, 45(12):569-581. 
152. Black AE, Goldberg GR, Jebb SA, Livingstone MB, Cole TJ, Prentice AM: Critical 
evaluation of energy intake data using fundamental principles of energy 
physiology: 2. Evaluating the results of published surveys. European journal of 
clinical nutrition 1991, 45(12):583-599. 
153. Gronn M, Gorbitz C, Christensen E, Levorsen A, Ose L, Hagve TA, Christophersen 
BO: Dietary n-6 fatty acids inhibit the incorporation of dietary n-3 fatty acids in 
thrombocyte and serum phospholipids in humans: a controlled dietetic study. 
Scandinavian journal of clinical and laboratory investigation 1991, 51(3):255-263. 
154. Norwegian Food Safety Authority DfHUoOhwnn: The Norwegian Food 
Composition Table 2006. In.; 2006. 
155. Black AE: The sensitivity and specificity of the Goldberg cut-off for EI:BMR for 
identifying diet reports of poor validity. European journal of clinical nutrition 
2000, 54(5):395-404. 
156. Warren AG, Janz BA, Slavin SA, Borud LJ: The use of bioimpedance analysis to 
evaluate lymphedema. Annals of plastic surgery 2007, 58(5):541-543. 
157. Ward LC, Czerniec S, Kilbreath SL: Quantitative bioimpedance spectroscopy for 
the assessment of lymphoedema. Breast cancer research and treatment 2009, 
117(3):541-547. 
158. Suresh K, Chandrashekara S: Sample size estimation and power analysis for 
clinical research studies. Journal of human reproductive sciences 2012, 5(1):7-13. 
159. Bingham SA, Cassidy A, Cole TJ, Welch A, Runswick SA, Black AE, Thurnham D, 
Bates C, Khaw KT, Key TJ et al: Validation of weighed records and other methods 
of dietary assessment using the 24 h urine nitrogen technique and other biological 
markers. The British journal of nutrition 1995, 73(4):531-550. 
160. Chapuy MC, Preziosi P, Maamer M, Arnaud S, Galan P, Hercberg S, Meunier PJ: 
Prevalence of vitamin D insufficiency in an adult normal population. Osteoporosis 
international : a journal established as result of cooperation between the European 
Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 
1997, 7(5):439-443. 
161. Meyer HE, Falch JA, Sogaard AJ, Haug E: Vitamin D deficiency and secondary 
hyperparathyroidism and the association with bone mineral density in persons 
with Pakistani and Norwegian background living in Oslo, Norway, The Oslo 
Health Study. Bone 2004, 35(2):412-417. 
162. National dietary survey among men and women age 18-70 years, 2010-2011. 
Norkost3 (Norwegian). The Norwegian Directorate of Health. ; 2012: 1-70. 
163. Johansson L SK: Norkost 1997. National dietary survey among men and women 
age 16-79 years. Report no. 2/1999 (in Norwegian). In.: The National Council on 
Nutrition and Physical Activity: Oslo.; 1999. 
164. Sokol RJ, Farrell MK, Heubi JE, Tsang RC, Balistreri WF: Comparison of vitamin E 
and 25-hydroxyvitamin D absorption during childhood cholestasis. The Journal of 
pediatrics 1983, 103(5):712-717. 
165. Issa S, Rotthauwe HW, Burmeister W: 25 Hydroxyvitamin D and vitamin E 
absorption in healthy children and children with chronic intrahepatic cholestasis. 
European journal of pediatrics 1989, 148(7):605-609. 
166. Dixon JB: Mechanisms of chylomicron uptake into lacteals. Annals of the New 
York Academy of Sciences 2010, 1207 Suppl 1:E52-57. 
68 
 
167. Meyer HE BL, Brustad M, Holvik K, Johansson L and Paulsen JE. : Tiltak for å sikre 
en god vitamin D-status i befolkningen. In.: Nasjonalt råd for ernæring. Sosial-og 
helsedirektoratet, Oslo, Norway; 2006. 
168. Vandewoude MF, Vandewoude MG: Vitamin E status in a normal population: the 
influence of age. Journal of the American College of Nutrition 1987, 6(4):307-311. 
169. Mata-Granados JM, Luque de Castro MD, Quesada Gomez JM: Inappropriate 
serum levels of retinol, alpha-tocopherol, 25 hydroxyvitamin D3 and 24,25 
dihydroxyvitamin D3 levels in healthy Spanish adults: simultaneous assessment 
by HPLC. Clinical biochemistry 2008, 41(9):676-680. 
170. Mustacich DJ, Bruno RS, Traber MG: Vitamin E. Vitamins and hormones 2007, 
76:1-21. 
171. Jiang Q: Natural forms of vitamin E: metabolism, antioxidant, and anti-
inflammatory activities and their role in disease prevention and therapy. Free 
radical biology & medicine 2014, 72C:76-90. 
172. Reiter E, Jiang Q, Christen S: Anti-inflammatory properties of alpha- and gamma-
tocopherol. Molecular aspects of medicine 2007, 28(5-6):668-691. 
173. Boris M, Weindorf S, Lasinkski S: Persistence of lymphedema reduction after 
noninvasive complex lymphedema therapy. Oncology 1997, 11(1):99-109; 
discussion 110, 113-104. 
174. Yamamoto R, Yamamoto T: Effectiveness of the treatment-phase of two-phase 
complex decongestive physiotherapy for the treatment of extremity lymphedema. 
International journal of clinical oncology 2007, 12(6):463-468. 
175. Hwang JH, Choi JY, Lee JY, Hyun SH, Choi Y, Choe YS, Lee KH, Kim BT: 
Lymphscintigraphy predicts response to complex physical therapy in patients 
with early stage extremity lymphedema. Lymphology 2007, 40(4):172-176. 
176. Morgan PA, Franks PJ, Moffatt CJ: Health-related quality of life with 
lymphoedema: a review of the literature. International wound journal 2005, 
2(1):47-62. 
177. Honnor A: Classification, aetiology and nursing management of lymphoedema. 
British journal of nursing 2008, 17(9):576-586. 
178. Feldman AG, Sokol RJ: Neonatal Cholestasis. NeoReviews 2013, 14(2). 
179. Lykavieris P, Hadchouel M, Chardot C, Bernard O: Outcome of liver disease in 
children with Alagille syndrome: a study of 163 patients. Gut 2001, 49(3):431-435. 
180. Quiros-Tejeira RE, Ament ME, Heyman MB, Martin MG, Rosenthal P, Hall TR, 
McDiarmid SV, Vargas JH: Variable morbidity in alagille syndrome: a review of 
43 cases. Journal of pediatric gastroenterology and nutrition 1999, 29(4):431-437. 
181. Emerick KM, Rand EB, Goldmuntz E, Krantz ID, Spinner NB, Piccoli DA: Features 
of Alagille syndrome in 92 patients: frequency and relation to prognosis. 
Hepatology 1999, 29(3):822-829. 
182. Hoffenberg EJ, Narkewicz MR, Sondheimer JM, Smith DJ, Silverman A, Sokol RJ: 
Outcome of syndromic paucity of interlobular bile ducts (Alagille syndrome) with 
onset of cholestasis in infancy. The Journal of pediatrics 1995, 127(2):220-224. 
183. Drouin E, Russo P, Tuchweber B, Mitchell G, Rasquin-Weber A: North American 
Indian cirrhosis in children: a review of 30 cases. Journal of pediatric 
gastroenterology and nutrition 2000, 31(4):395-404. 
184. Nielsen IM, Eiberg H: Cholestasis Familiaris Groenlandica: an epidemiological, 
clinical and genetic study. International journal of circumpolar health 2004, 63 
Suppl 2:192-194. 
69 
 
185. Klomp LW, Bull LN, Knisely AS, van Der Doelen MA, Juijn JA, Berger R, Forget S, 
Nielsen IM, Eiberg H, Houwen RH: A missense mutation in FIC1 is associated with 
greenland familial cholestasis. Hepatology 2000, 32(6):1337-1341. 
186. Morotti RA, Suchy FJ, Magid MS: Progressive familial intrahepatic cholestasis 
(PFIC) type 1, 2, and 3: a review of the liver pathology findings. Seminars in liver 
disease 2011, 31(1):3-10. 
187. Cooper DN, Krawczak M, Polychronakos C, Tyler-Smith C, Kehrer-Sawatzki H: 
Where genotype is not predictive of phenotype: towards an understanding of the 
molecular basis of reduced penetrance in human inherited disease. Human 
genetics 2013, 132(10):1077-1130. 
 
 
70 
List of errata 
In section 9.2.4 at page 54, line 8 it is written ”Additionally, it is likely that 2 adults 
died due to liver disease before reaching old (> 70 years) age 11/39 = 0.28 i.e. 28%. 
Summarised this yields a survival rate of about 72%.”  
The correct sentence is ”Additionally, one adult patient died due to liver disease 
before reaching old (> 70 years) age 10/39 = 0.26 i.e. 26%. Summarised this yields a 
survival rate of about 74%.”  
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Appendix 1

“Oppfølgingsundersøkelse av personer med Aagenæs syndrom”
Senter for sjeldne diagnoser, Oslo universitetssykehus, Rikshospitalet
Monica Drivdal,   Tlf: 95 97 56 16   E-post: uxildr@rikshospitalet.no
Lymfødemanamnese
Navn (blokkbokstaver)_______________________________________________ 
Kryss av i den boksen, og noter ned det som stemmer mest for deg. Ved 
noen spørsmål er det nødvendig og/eller mulig å krysse av flere.
1. Har du lymfødem? Ja ͔ Nei ͔ Av og til ͔
2. Hvor mange dager siden er det du brukte bandasjer/kompresjonsstrømper/
behandling for lymfødemet?
4 dager ͔ 5-10 dager ͔ Mer enn 10 dager ͔ Annet ______________
3. Opplever du ditt lymfødem som plagsomt?  Ja ͔     Nei ͔
4. Når ble lymfødemet påvist hos deg? Noter din alder _____ eller årstall _____
5. Når startet du behandling? Noter din alder _______  eller årstall  ________
6. Bruker du å bandasjere beina dine?     Ja alltid ͔    Nei ͔ Av og til ͔
7. Bruker du elastiske kompresjonsstrømper?     Ja alltid ͔ Nei ͔     Av og til ͔
8. Rekker kompresjonstrømper/ bandasje opp til: Kneet ͔ Lysken ͔ Bukse  ͔
9. Sover du med beina hevet? Ja alltid ͔   Nei ͔     Av og til  ͔
10.Bruker du pulsator? Ja regelmessig ͔    Nei ͔ Av og til ͔
11.Får du lymfedrenasje hos fysioterapeut? Ja ͔ Hvor ofte _________    Nei ͔
12.Har du hatt behov for intensiv lymfedrenasje behandling?  Ja ͔Hvor ofte ____
         Nei  ͔     
13.Hva bestod lymfødembehandlingen av i puberteten? Bandasjering ͔
Kompresjonsstrømper ͔  Pulsator ͔      Lymfedrenasje ͔          Ikke noe ͔  
14.Har du noen form for fysisk aktivitet utover vanlige dagligdagse gjøremål, eller
går du i skogen/ terrenget/ på ujevnt underlag?              Ja ͔ Nei ͔
15.Opplever du at du er mindre mobil/ bevegelig pga lymfødemet? Ja ͔Nei ͔
“Oppfølgingsundersøkelse av personer med Aagenæs syndrom”
Senter for sjeldne diagnoser, Oslo universitetssykehus, Rikshospitalet
Monica Drivdal,   Tlf: 95 97 56 16   E-post: uxildr@rikshospitalet.no
16.Opplever du sideforskjeller, som f.eks det ene beinet har mer lymfødem enn
det andre?    Ja ͔Nei ͔
17.Vet du at du har ͔, eller opplever du ͔å ha lymfødem andre steder på 
kroppen som hender ͔, armer ͔, ansikt ͔, mage ͔, brysthule ͔?
18.Opplever du tyngdefølelse ͔, (spreng)smerte ͔ eller andre tilsvarende
symptomer fra ditt lymfødem?                                                       Ja ͔ Nei ͔
                             Hvis ja, Daglig ͔ Ukentlig ͔Av og til ͔Sjeldent ͔Aldri ͔
19.Har du hatt infeksjon (rosen/ erysipelas) i huden?           Ja ͔Nei ͔
Hvis ja, hvor mange ganger? _________
20.Hvor ofte smører du huden din på lymfødemutsatte områder med salve/ lotion/ 
krem? 
           Daglig ͔ Ukentlig ͔Sjeldent ͔     Aldri ͔
21. Har du ortopedisk tilpasset skotøy?                                              Ja ͔Nei ͔
22.Hva slags behandling har du fått for hevelsen du har i beina dine? Kryss av 
det som passer:
a. ͔Ingen 
b. ͔Lymfødebehandling
c. ͔Bandasjering
d. ͔Jeg bruker kompresjonsstrømper
e. ͔Pulsator
f. ͔Spesielle øvelser
